"document"	"useremail"	"claimlabel"	"claimtext"	"method"	"relationship"	"drug1"	"drug2"	"precipitant"	"enzyme"	"rejected"	"evRelationship"	"participants"	"participantstext"	"drug1dose"	"drug1formulation"	"drug1duration"	"drug1regimens"	"drug1dosetext"	"drug2dose"	"phenotypetype"	"phenotypevalue"	"phenotypemetabolizer"	"phenotypepopulation"	"drug2formulation"	"drug2duration"	"drug2regimens"	"drug2dosetext"	"aucvalue"	"auctype"	"aucdirection"	"auctext"	"cmaxvalue"	"cmaxtype"	"cmaxdirection"	"cmaxtext"	"clearancevalue"	"clearancetype"	"clearancedirection"	"clearancetext"	"halflifevalue"	"halflifetype"	"halflifedirection"	"halflifetext"	"dipsquestion"	"reviewer"	"reviewerdate"	"reviewertotal"	"reviewerlackinfo"	"grouprandomization"	"parallelgroupdesign"	"id"
"http://localhost/wolters/wolters17108811.html"	"annotat4@gmail.com"	"simvastatin_substrate of_OATP1B1"	"The SLCO1B1 genotype was significantly associated with the pharmacokinetics of simvastatin acid, but not with those of the parent simvastatin lactone"	"Phenotype clinical study"	"substrate of"	"simvastatin"	""	""	"OATP1B1"	""	"supports"	"32"	"A total of 32 young healthy Caucasian volunteers participated in the study after giving written informed consent."	"40"	"UNK"	"UNK"	"UNK"	""	""	"Genotype"	"UNK"	""	"Caucasian"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVnQZLk81_rzbHfMC-Uw"
"http://localhost/wolters/wolters17108811.html"	"annotat4@gmail.com"	"simvastatin acid_substrate of_OATP1B1"	"The SLCO1B1 genotype was significantly associated with the pharmacokinetics of simvastatin acid, but not with those of the parent simvastatin lactone"	"Phenotype clinical study"	"substrate of"	"simvastatin acid"	""	""	"OATP1B1"	""	"supports"	"32"	"A total of 32 young healthy Caucasian volunteers participated in the study after giving written informed consent"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVnQWbfI1_rzbHfMC-Uu"
"http://localhost/sage/sage15069169.html"	"annotat4@gmail.com"	"amiodarone_interact with_simvastatin"	"Due to a suspected drug interaction of simvastatin with amiodarone, both drugs were stopped"	"DDI clinical trial"	"interact with"	"amiodarone"	"simvastatin"	"drug1"	""	""	"supports"	"1"	"A 63-year-old white man with underlying insulin-dependent diabetes, recent coronary artery bypass surgery, and postoperative hemiplegia was treated with aspirin, metoprolol, furosemide, nitroglycerin, and simvastatin. Due to recurrent atrial fibrillation, oral anticoagulation with phenprocoumon and antiarrhythmic treatment with amiodarone were initiated. Four weeks after starting simvastatin 40 mg/day and 2 weeks after initiating amiodarone 1 g/day for 10 days, then 200 mg/day, he developed diffuse muscle pain with generalized muscular weakness"	"40"	"UNK"	"28"	"Daily"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVnP4tzp1_rzbHfMC-Un"
"http://localhost/wolters/wolters12172351.html"	"annotat4@gmail.com"	"fluoxetine_interact with_tramadol"	"A case of a serotonin syndrome after concurrent administration of fluoxetine and tramadol has been previously demonstrated. 4 We report on another case of full-blown serotonin syndrome attributed to this combination following an increase of the tramadol dose. Symptoms gradually resolved after drug discontinuation parallel to decreasing fluoxetine plasma levels."	"Case Report"	"interact with"	"fluoxetine"	"tramadol"	"drug1"	""	""	""	""	""	"80"	"UNK"	"56"	"SD"	""	"800"	""	""	""	""	"UNK"	"UNK"	"UNK"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|Yes|Yes|Yes|NA|UNK/NA|Yes|UNK/NA|Yes|NA"	"External"	"01/24/2017"	4	""	""	""	"AVnPulXh1_rzbHfMC-Uk"
"http://localhost/wolters/wolters17921794.html"	"annotat4@gmail.com"	"colchicine_interact with_simvastatin"	"We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis."	"Case Report"	"interact with"	"colchicine"	"simvastatin"	"drug1"	""	""	""	""	""	"80"	"UNK"	"UNK"	"QD"	""	"0.6"	""	""	""	""	"UNK"	"UNK"	"BID"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	"External"	"01/24/2017"	"NA"	""	""	""	"AVnPZBdq1_rzbHfMC-Ue"
"http://localhost/wolters/wolters22561472.html"	"annotat4@gmail.com"	"valproate_interact with_Quetiapine"	"Quetiapine was titrated to 100 mg/d on day 6. Laboratory data showed neutropenia on day 7. His WBC count was 2.59 × 109/L, and absolute neutrophil count (ANC) was 1.748 × 109/L. Both quetiapine and valproate were immediately discontinued"	"Case Report"	"interact with"	"valproate"	"Quetiapine"	"drug1"	""	""	""	""	""	"200"	"UNK"	"1"	"SD"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	"01/24/2017"	"NA"	""	""	""	"AVnPIDGe1_rzbHfMC-UX"
"http://localhost/wolters/wolters22217948.html"	"annotat4@gmail.com"	"quetiapine_interact with_VPA"	"To our knowledge, this is the first report on the occurrence of neutropenia and thrombocytopenia associated with concomitant VPA and quetiapine use after lamotrigine-induced SJS in a patient with bipolar disorder."	"Case Report"	"interact with"	"quetiapine"	"VPA"	""	""	""	""	""	""	"400"	"UNK"	"UNK"	"UNK"	""	"500"	""	""	""	""	"UNK"	"UNK"	"UNK"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"No|Yes|Yes|Yes|NA|UNK/NA|Yes|UNK/NA|NA|NA"	"External"	"01/24/2017"	1	""	""	""	"AVnPDyGF1_rzbHfMC-US"
"http://localhost/wolters/wolters15319707.html"	"annotat4@gmail.com"	"bupropion_interact with_clomipramine"	"One week after the start of bupropion SR 300 mg/d, Miss A. had generalized tonic-clonic movements, accompanied by unresponsiveness for about 5 minutes. She was transported to an emergency department, where an EEG revealed very frequent generalized spike and wave complexes on both hemispheres. This pattern was prominent on the frontal area with occasional generalization (Fig. 2). Her physical and neurologic examination was normal. On laboratory investigation, urinalysis, complete blood count, serum electrolytes, and renal and liver function test results were normal. Although bupropion SR was discontinued, a similar generalized seizure occurred 3 days later. She was switched from clomipramine to sertraline, after which no further seizures have been reported"	"Case Report"	"interact with"	"bupropion"	"clomipramine"	"drug1"	""	""	""	""	""	"300"	"UNK"	"1"	"SD"	""	"25"	""	""	""	""	"UNK"	"1"	"SD"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"NA|No|Yes|Yes|NA|UNK/NA|Yes|UNK/NA|NA|NA"	"External"	"01/24/2017"	""	""	""	""	"AVnO70eq1_rzbHfMC-UN"
"http://localhost/wolters/wolters7782487.html"	"annotat4@gmail.com"	"valproic acid_interact with_warfarin"	"She was transferred to the psychiatry service, where she ultimately agreed to take her psychiatric medications. Valproic acid, 250 mg twice daily, and fluphenazine, 5 mg once daily, were added to her warfarin regimen. On the morning after her first dose of valproic acid, the PT ratio increased to 2.0 and the INR increased to 3.9. In response, her coumadin dose was decreased to 2.5 mg every other day until her PT and INR returned to the normal range"	"Case Report"	"interact with"	"valproic acid"	"warfarin"	"drug1"	""	""	""	""	""	"500"	"UNK"	"daily"	"BID"	""	"5.0"	""	""	""	""	"Oral"	"daily"	"Daily"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|Yes|Yes|Yes|NA|No|UNK/NA|UNK/NA|Yes|NA"	"External"	"01/23/2017"	4	""	""	""	"AVnOw4ex1_rzbHfMC-UJ"
"http://localhost/wolters/wolters9004070.html"	"annotat4@gmail.com"	"venlafaxine_interact with_selegiline"	"On the 16th day after selegiline discontinuation, he was placed on venlafaxine, 37.5 mg. Within 30 minutes, he noted the onset of profound anxiety, diarrhea, myoclonic jerks, shivering, tremor, and profuse diaphoresis. He went to the emergency department where he was afebrile, with a pulse of 110, and blood pressure of 143/90"	"Case Report"	"interact with"	"venlafaxine"	"selegiline"	"drug1"	""	""	""	""	""	"37.5"	"UNK"	"UNK"	"UNK"	""	"50"	""	""	""	""	"UNK"	"UNK"	"UNK"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|Yes|Yes|No|NA|UNK/NA|UNK/NA|UNK/NA|Yes|NA"	"External"	"01/23/2017"	3	""	""	""	"AVnOnL331_rzbHfMC-UF"
"http://localhost/wolters/wolters15545884.html"	"annotat4@gmail.com"	"clarithromycin_interact with_simvastatin"	"A 77-year-old man with dyslipidemia treated with simvastatin was prescribed a course of clarithromycin by his general practitioner for an upper respiratory tract infection. He subsequently presented to the hospital with generalized muscle pain, weakness, and inability to walk"	"Case Report"	"interact with"	"clarithromycin"	"simvastatin"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVnK-vmx1_rzbHfMC-T-"
"http://localhost/wolters/wolters15545884.html"	"annotat4@gmail.com"	"clarithromycin_interact with_simvastatin"	"A 77-year-old man with dyslipidemia treated with simvastatin was prescribed a course of clarithromycin by his general practitioner for an upper respiratory tract infection. He subsequently presented to the hospital with generalized muscle pain, weakness, and inability to walk"	"Case Report"	"interact with"	"clarithromycin"	"simvastatin"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVnK9k0V1_rzbHfMC-T8"
"http://localhost/sage/sage15069169.html"	"annotat4@gmail.com"	"amiodarone_interact with_simvastatin"	"Due to a suspected drug interaction of simvastatin with amiodarone, both drugs were stopped"	"Case Report"	"interact with"	"amiodarone"	"simvastatin"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVnK4BVV1_rzbHfMC-T4"
"http://localhost/sage/sage15956236.html"	"annotat4@gmail.com"	"fluvastatin_interact with_colchicine"	"He had been taking fluvastatin 80 mg/day for 2 years, and for 10 days before presentation, he had also been taking colchicine 1.5 mg/day for acute gouty arthritis. Three days after initiation of colchicine therapy, the man started reporting stomach ache and nausea. He later developed increasingly severe pains in his arms and legs as well as weakness."	"Case Report"	"interact with"	"fluvastatin"	"colchicine"	"drug1"	""	""	""	""	""	"80"	"UNK"	"730"	"QD"	""	"1.5"	""	""	""	""	"UNK"	"1"	"QD"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"No|Yes|Yes|Yes|NA|UNK/NA|Yes|UNK/NA|Yes|NA"	"External"	"01/23/2017"	2	""	""	""	"AVnKtr0u1_rzbHfMC-Tz"
"http://localhost/sage/sage15914514.html"	"annotat4@gmail.com"	"pravastatin_interact with_colchicine"	"She had been taking pravastatin 20 mg once daily for 6 years. On admission, blood urea nitrogen and serum creatinine levels were 48 mg/dL and 1.3 mg/dL, respectively. Colchicine 1.5 mg/day was added to the treatment regimen, but 20 days after the initiation of colchicine therapy, symmetrical proximal muscle weakness developed in the woman's legs. Physical examination, laboratory findings, and electromyelogram findings suggested myopathy"	"Case Report"	"interact with"	"pravastatin"	"colchicine"	"drug1"	""	""	""	""	""	"20"	"UNK"	"2190"	"QD"	""	"1.5"	""	""	""	""	"UNK"	"1"	"QD"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"No|Yes|Yes|Yes|NA|UNK/NA|Yes|UNK/NA|Yes|NA"	"External"	"01/23/2017"	2	""	""	""	"AVnKljp11_rzbHfMC-Tu"
"http://localhost/taylorFrancis/taylor17931461.html"	"annotat4@gmail.com"	"simvastatin_interact with_vildagliptin"	"The 90% confidence intervals of C(max) and AUC(tau) of vildagliptin, simvastatin, and simvastatin beta-hydroxy acid were between 80 and 125% (bioequivalence range) when vildagliptin and simvastatin were admin istered alone and in combination. These data indicate that the rate and extent of absorption of vildagliptin and simvastatin were not affected when co-administered, nor was the metabolic conversion of simvastatin to its active metabolite. All treatments were safe and well tolerated in this study.CONCLUSIONS: The pharmacokinetics of vildagliptin, simvastatin, and its active metabolite were not altered when vildagliptin and simvastatin were co-administered"	"DDI clinical trial"	"interact with"	"simvastatin"	"vildagliptin"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVnKTeMj1_rzbHfMC-Tp"
"http://localhost/taylorFrancis/taylor17931461.html"	"annotat4@gmail.com"	"vildagliptin_interact with_simvastatin"	"The 90% confidence intervals of C(max) and AUC(tau) of vildagliptin, simvastatin, and simvastatin beta-hydroxy acid were between 80 and 125% (bioequivalence range) when vildagliptin and simvastatin were admin istered alone and in combination. These data indicate that the rate and extent of absorption of vildagliptin and simvastatin were not affected when co-administered, nor was the metabolic conversion of simvastatin to its active metabolite. All treatments were safe and well tolerated in this study.CONCLUSIONS: The pharmacokinetics of vildagliptin, simvastatin, and its active metabolite were not altered when vildagliptin and simvastatin were co-administered"	"DDI clinical trial"	"interact with"	"vildagliptin"	"simvastatin"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVnKSbD91_rzbHfMC-To"
"http://localhost/elsevier/elsevier14984623.html"	"annotat4@gmail.com"	"linezolid_interact with_citalopram"	"Once the drug–drug interaction between linezolid, a monoamine oxidase inhibitor and citalopram, a selective serotonin reuptake inhibitor (SSRI), was identified, citalopram was discontinued"	"Case Report"	"interact with"	"linezolid"	"citalopram"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	"External"	"01/23/2017"	"NA"	""	""	""	"AVnKGkkO1_rzbHfMC-Th"
"http://localhost/springer/springer18193210.html"	"annotat4@gmail.com"	"atorvastatin_interact with_verapamil"	"Pharmacokinetics of verapamil were significantly altered by the coadministration of atorvastatin compared with those of without atorvastatin. For example, the total area under the plasma-concentration time curve to the last measured time, 24 h, in plasma (AUC0−24 h) of verapamil increased significantly by 42.8%"	"DDI clinical trial"	"interact with"	"atorvastatin"	"verapamil"	"drug1"	""	""	"supports"	"12"	"Twelve healthy male Korean volunteers with an age of 23.8 ± 1.42 (range 22–27) years, weight of 66.3 ± 2.58  (range 61–70) kg, and height of 172 ± 4.04  (range 164–178) cm participated in the study"	"40"	"Oral"	"UNK"	"UNK"	""	"60"	""	""	""	""	"Oral"	"UNK"	"UNK"	""	"42.8"	"Percent"	"Increase"	"Mean (± standard deviation) pharmacokinetic parameters of verapamil and norverapamil after oral administration of verapamil (60 mg) in the presence or absence of oral atorvastatin (40 mg) in healthy subjects (n = 12)"	"22.5"	"Percent"	"Increase"	"Mean (± standard deviation) pharmacokinetic parameters of verapamil and norverapamil after oral administration of verapamil (60 mg) in the presence or absence of oral atorvastatin (40 mg) in healthy subjects (n = 12)"	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVmW1Hmu1_rzbHfMC-RJ"
"http://localhost/springer/springer18193210.html"	"annotat4@gmail.com"	"atorvastatin_interact with_norverapamil"	"Although the AUC0−24 h of norverapamil was not significantly different between two groups of humans, the AUC0−24 h, norverapamil/ AUC0−24 h, verapamil ratio was significantly reduced (27.5% decrease) with atorvastatin."	"DDI clinical trial"	"interact with"	"atorvastatin"	"norverapamil"	"drug1"	""	""	"supports"	"12"	"Twelve healthy male Korean volunteers with an age of 23.8 ± 1.42 (range 22–27) years, weight of 66.3 ± 2.58  (range 61–70) kg, and height of 172 ± 4.04  (range 164–178) cm participated in the study"	"40"	"Oral"	"UNK"	"UNK"	""	""	""	""	""	""	""	""	""	""	"unchanged"	""	""	"Although the AUC0−24 h of norverapamil was not significantly different between two groups of humans"	"4.3"	"Percent"	"Increase"	"Mean (± standard deviation) pharmacokinetic parameters of verapamil and norverapamil after oral administration of verapamil (60 mg) in the presence or absence of oral atorvastatin (40 mg) in healthy subjects (n = 12)"	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVmrwJgd1_rzbHfMC-Sp"
"http://localhost/wiley/wiley19204138.html"	"annotat4@gmail.com"	"sitagliptin_interact with_simvastatin"	"coadministration of sitagliptin and simvastatin had no meaningful effect on the pharmacokinetics for active HMG-CoA reductase inhibitors, with a GMR (90% CI) for AUC0-last and Cmax of 1.06 (0.88, 1.26) and 0.94 (0.66, 1.34), respectively"	"DDI clinical trial"	"interact with"	"sitagliptin"	"simvastatin"	"drug1"	""	""	"refutes"	"12"	"The 12 subjects (9 men and 3 women) randomized in this study"	"200"	"Oral"	"5"	"QD"	""	"20"	""	""	""	""	"Oral"	"1"	"SD"	""	"unchanged"	""	""	"there were no clinically or statistically meaningful differences in AUC0-last, Cmax, or Tmax between treatments for the other 3 analytes evaluated (Table I and Figure 1B-D)."	"unchanged"	""	""	"there were no clinically or statistically meaningful differences in AUC0-last, Cmax, or Tmax between treatments for the other 3 analytes evaluated (Table I and Figure 1B-D)."	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVmWLe7U1_rzbHfMC-Q4"
"http://localhost/springer/springer12603176.html"	"annotat4@gmail.com"	"simvastatin_interact with_bosentan"	"The pharmacokinetic parameters of bosentan and its metabolites were not influenced by concomitant treatment with simvastatin: areas under the plasma concentration-time curve over one administration interval of 12 hours (AUCτ) [geometric mean and 95% CI] were 4586 (3719–5656) and 4928 (3945–6156) μg · h/L."	"DDI clinical trial"	"interact with"	"simvastatin"	"bosentan"	"drug1"	""	""	"refutes"	"9"	"Nine healthy male subjects were treated in a three-period randomised crossover study with: (A) bosentan 125mg twice daily for 5.5 days; (B) simvastatin 40mg once daily for 6 days; and (C) bosentan 125mg twice daily and simvastatin 40mg once daily for 5.5 and 6 days, respectively. Plasma concentration-time profiles of bosentan and its metabolites (treatments A and C) and simvastatin and β-hydroxyacid simvastatin (treatments B and C) were determined on day 6"	"40"	"UNK"	"6"	"QD"	""	"125"	""	""	""	""	"UNK"	"5.5"	"BID"	""	"unchanged"	""	""	"The derived pharmacokinetic parameters of bosentan and its metabolites are presented in table I. ANOVA did not yield any statistically significant differences between the two treatments"	"unchanged"	""	""	"The derived pharmacokinetic parameters of bosentan and its metabolites are presented in table I. ANOVA did not yield any statistically significant differences between the two treatments"	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVmWhPyt1_rzbHfMC-RC"
"http://localhost/springer/springer19071883.html"	"annotat2@gmail.com"	"simvastatin_interact with_mipomersen sodium"	"The area under the plasma concentration-time curve (AUC) from 0 to 24 hours (AUC(24)), maximum plasma concentration and apparent elimination half-life values of mipomersen sodium were similar when administered alone and in combination with oral simvastatin or oral ezetimibe. The 90% confidence intervals of the geometric least squares means ratios (%Reference) of the mipomersen sodium AUC(24) values were 93.6, 107 when administered together with simvastatin, and 92.4, 111 when administered with ezetimibe. Therefore, there were no large deviations outside the default no-effect boundaries (80-125%) for total exposure (the AUC) of mipomersen sodium in combination with either simvastatin or ezetimibe. Similarly, large deviations outside the default no-effect boundaries were not observed for simvastatin, simvastatin acid, or free and total ezetimibe exposure in combination with mipomersen sodium."	"DDI clinical trial"	"interact with"	"simvastatin"	"mipomersen sodium"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVmntOXy1_rzbHfMC-Sa"
"http://localhost/springer/springer19071883.html"	"annotat2@gmail.com"	"ezetimibe_interact with_mipomersen sodium"	"The area under the plasma concentration-time curve (AUC) from 0 to 24 hours (AUC(24)), maximum plasma concentration and apparent elimination half-life values of mipomersen sodium were similar when administered alone and in combination with oral simvastatin or oral ezetimibe. The 90% confidence intervals of the geometric least squares means ratios (%Reference) of the mipomersen sodium AUC(24) values were 93.6, 107 when administered together with simvastatin, and 92.4, 111 when administered with ezetimibe. Therefore, there were no large deviations outside the default no-effect boundaries (80-125%) for total exposure (the AUC) of mipomersen sodium in combination with either simvastatin or ezetimibe. Similarly, large deviations outside the default no-effect boundaries were not observed for simvastatin, simvastatin acid, or free and total ezetimibe exposure in combination with mipomersen sodium"	"DDI clinical trial"	"interact with"	"ezetimibe"	"mipomersen sodium"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVmntBNJ1_rzbHfMC-SZ"
"http://localhost/springer/springer19071883.html"	"annotat2@gmail.com"	"mipomersen sodium_interact with_ezetimibe"	"The area under the plasma concentration-time curve (AUC) from 0 to 24 hours (AUC(24)), maximum plasma concentration and apparent elimination half-life values of mipomersen sodium were similar when administered alone and in combination with oral simvastatin or oral ezetimibe. The 90% confidence intervals of the geometric least squares means ratios (%Reference) of the mipomersen sodium AUC(24) values were 93.6, 107 when administered together with simvastatin, and 92.4, 111 when administered with ezetimibe. Therefore, there were no large deviations outside the default no-effect boundaries (80-125%) for total exposure (the AUC) of mipomersen sodium in combination with either simvastatin or ezetimibe. Similarly, large deviations outside the default no-effect boundaries were not observed for simvastatin, simvastatin acid, or free and total ezetimibe exposure in combination with mipomersen sodium."	"DDI clinical trial"	"interact with"	"mipomersen sodium"	"ezetimibe"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVmnsplr1_rzbHfMC-SY"
"http://localhost/springer/springer19071883.html"	"annotat2@gmail.com"	"mipomersen sodium_interact with_simvastatin"	"The area under the plasma concentration-time curve (AUC) from 0 to 24 hours (AUC(24)), maximum plasma concentration and apparent elimination half-life values of mipomersen sodium were similar when administered alone and in combination with oral simvastatin or oral ezetimibe. The 90% confidence intervals of the geometric least squares means ratios (%Reference) of the mipomersen sodium AUC(24) values were 93.6, 107 when administered together with simvastatin, and 92.4, 111 when administered with ezetimibe. Therefore, there were no large deviations outside the default no-effect boundaries (80-125%) for total exposure (the AUC) of mipomersen sodium in combination with either simvastatin or ezetimibe. Similarly, large deviations outside the default no-effect boundaries were not observed for simvastatin, simvastatin acid, or free and total ezetimibe exposure in combination with mipomersen sodium."	"DDI clinical trial"	"interact with"	"mipomersen sodium"	"simvastatin"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVmnsUXz1_rzbHfMC-SX"
"http://localhost/springer/springer17216557.html"	"annotat4@gmail.com"	"ketoconazole_interact with_lovastatin"	"we report a case of hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy."	"Case Report"	"interact with"	"ketoconazole"	"lovastatin"	"drug1"	""	""	""	""	""	"400"	"Oral"	"UNK"	"TID"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|Yes|Yes|Yes|NA|UNK/NA|UNK/NA|UNK/NA|Yes|NA"	"External"	"01/16/2017"	5	""	""	""	"AVmmpbFr1_rzbHfMC-SL"
"http://localhost/springer/springer17624521.html"	"annotat4@gmail.com"	"ciprofloxacin_interact with_clozapine"	"We report a case of similar pharmacokinetic interaction between ciprofloxacin and clozapine, as demonstrated by Raaska et al., but to a much higher degree (i.e. a 500% increase in clozapine levels)."	"Case Report"	"interact with"	"ciprofloxacin"	"clozapine"	"drug1"	""	""	""	""	""	"500"	"UNK"	"14"	"BID"	""	"750"	""	""	""	""	"UNK"	"4"	"QD"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|Yes|Yes|Yes|NA|UNK/NA|Yes|Yes|NA|NA"	"External"	"01/16/2017"	4	""	""	""	"AVmm1K4E1_rzbHfMC-SR"
"http://localhost/springer/springer16328318.html"	"annotat2@gmail.com"	"BAY 59-7939_inhibits_UNK"	"Dose-proportional pharmacokinetics (AUC(tau, norm) and C(max, norm)) were observed at steady state (day 7). Maximum plasma concentrations were achieved after 3-4 h. The terminal half-life of BAY 59-7939 was 5.7-9.2 h at steady state. There was no relevant accumulation at any dose."	"Phenotype clinical study"	"inhibits"	"BAY 59-7939"	""	""	"UNK"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVmmfe5I1_rzbHfMC-SD"
"http://localhost/springer/springer7875191.html"	"annotat2@gmail.com"	"simvastatin_interact with_ramipril"	"The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1. The urinary excretion of ramipril+metabolites for (R+P) and (R+S) was 25.2 and 24.1% of dose. The maximum percentage inhibition of ACE-activity for (R+P) was 94.6%, and for (R+S) it was 94.1%. It is concluded that concomitant administration of simvastatin and ramipril has no clinically relevant effect on the pharmacokinetics or ACE-inhibition of the latter drug and its metabolites."	"DDI clinical trial"	"interact with"	"simvastatin"	"ramipril"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVmmQKFo1_rzbHfMC-R8"
"http://localhost/springer/springer22922682.html"	"annotat4@gmail.com"	"ticagrelor_interact with_simvastatin"	"For simvastatin, volunteers (n = 24) received simvastatin 80 mg, or ticagrelor (loading dose 270 mg; 180 mg twice daily, 7 days) plus simvastatin (80 mg; day 5)"	"DDI clinical trial"	"interact with"	"ticagrelor"	"simvastatin"	"drug1"	""	""	"supports"	"24"	"Of the 24 volunteers randomised and treated in the simvastatin study, 18 (75 %) were male, 14 (58 %) were Caucasian, and 10 (42 %) were black"	"180"	"Oral"	"7"	"BID"	""	"80"	""	""	""	""	"Oral"	"1"	"SD"	""	"56"	"Percent"	"Increase"	"Simvastatin Cmax and AUC were increased by 81 % and 56 % with ticagrelor."	"81"	"Percent"	"Increase"	"Simvastatin Cmax and AUC were increased by 81 % and 56 % with ticagrelor."	""	""	""	""	"unchanged"	""	""	"Simvastatin tmax and t½ values were similar with or without co-administration of ticagrelor"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVml8_I11_rzbHfMC-Rr"
"http://localhost/springer/springer22922682.html"	"annotat4@gmail.com"	"Ticagrelor_interact with_atorvastatin"	"Ticagrelor increased mean atorvastatin maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from zero to infinity (AUC) by 23 % and 36 %, respectively."	"DDI clinical trial"	"interact with"	"Ticagrelor"	"atorvastatin"	"drug1"	""	""	"supports"	"24"	"Of the 24 volunteers randomised and treated in the atorvastatin study, 19 (79 %) were male; 18 were Hispanic (75 %), five (21 %) were black, and one (4 %) was Caucasian. Mean (standard deviation [SD]) age was 32.5 (8.8) years and mean (SD) BMI was 24.8 (2.9) kg/m2"	"90"	"Oral"	"7"	"BID"	""	"80"	""	""	""	""	"Oral"	"1"	"SD"	""	"36"	"Percent"	"Increase"	"The atorvastatin median tmax was unchanged during co-administration with ticagrelor (Table 1). However, relative to administration with placebo, Cmax and AUC of atorvastatin were increased in the presence of ticagrelor (Table 1, Fig. 2a): Cmax increased by 23 % and AUC by 36 %"	"23"	"Percent"	"Increase"	"The atorvastatin median tmax was unchanged during co-administration with ticagrelor (Table 1). However, relative to administration with placebo, Cmax and AUC of atorvastatin were increased in the presence of ticagrelor (Table 1, Fig. 2a): Cmax increased by 23 % and AUC by 36 %"	""	""	""	""	"unchanged"	""	""	"However, in general, tmax and t½ of the atorvastatin metabolites were unchanged during ticagrelor co-administration"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVmliJsL1_rzbHfMC-Ra"
"http://localhost/springer/springer15625612.html"	"annotat2@gmail.com"	"fluconazole_interact with_atorvastatin"	"to our knowledge, there are no reported cases of rhabdomyolysis associated with concomitant intake of fluconazole and atorvastatin. We describe a fatal case of rhabdomyolysis in a 76-year-old male after use of this drug combination."	"Case Report"	"interact with"	"fluconazole"	"atorvastatin"	"drug1"	""	""	""	""	""	"150"	"UNK"	"547.5"	"Daily"	""	"40"	""	""	""	""	"UNK"	"7"	"Daily"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|Yes|Yes|Yes|NA|UNK/NA|Yes|UNK/NA|Yes|NA"	"External"	"01/16/2017"	4	""	""	""	"AVmlxI1u1_rzbHfMC-Rk"
"http://localhost/springer/springer23831870.html"	"annotat4@gmail.com"	"rifampin_interact with_pitavastatin"	"Co-treatment of rifampin significantly increased the Cmax of pitavastatin by 819.2 % (95 % C I, 515.4–1123.0 %, p < 0.001) and the AUC(0–48 h) by 573.5 % (95 % CI, 373.3–773.7 %, p < 0.001). Co-treating with rifampin, the CL/F of pitavastatin was significantly decreased by 81.4  %(95 % CI, 75.0–87.7 %, p < 0.001)"	"DDI clinical trial"	"interact with"	"rifampin"	"pitavastatin"	"drug1"	""	""	"supports"	"12"	"Twelve unrelated healthy adult men (mean ± SD: age 24.1 ± 1.9 years; mass index 25.6 ± 4.3 kg/m2) were recruited for the study."	"600"	"Oral"	"UNK"	"SD"	""	"4"	""	""	""	""	"Oral"	"Unk"	"SD"	""	"573.5"	"Percent"	"Increase"	"Co-treatment of rifampin significantly increased the Cmax of pitavastatin by 819.2 % (95 % C I, 515.4–1123.0 %, p < 0.001) and the AUC(0–48 h) by 573.5 % (95 % CI, 373.3–773.7 %, p < 0.001). Co-treating with rifampin, the CL/F of pitavastatin was significantly decreased by 81.4  %(95 % CI, 75.0–87.7 %, p < 0.001) compared with non co-treatment of rifampin. Meanwhile, rifampin decreased the t1/2 of pitavastatin by 38.8 % (95 % CI, 18.2–59.4 %, p < 0.001)"	"819.2"	"Percent"	"Increase"	"Co-treatment of rifampin significantly increased the Cmax of pitavastatin by 819.2 % (95 % C I, 515.4–1123.0 %, p < 0.001) and the AUC(0–48 h) by 573.5 % (95 % CI, 373.3–773.7 %, p < 0.001). Co-treating with rifampin, the CL/F of pitavastatin was significantly decreased by 81.4  %(95 % CI, 75.0–87.7 %, p < 0.001) compared with non co-treatment of rifampin. Meanwhile, rifampin decreased the t1/2 of pitavastatin by 38.8 % (95 % CI, 18.2–59.4 %, p < 0.001)"	"81.4"	"Percent"	"Decrease"	"Co-treatment of rifampin significantly increased the Cmax of pitavastatin by 819.2 % (95 % C I, 515.4–1123.0 %, p < 0.001) and the AUC(0–48 h) by 573.5 % (95 % CI, 373.3–773.7 %, p < 0.001). Co-treating with rifampin, the CL/F of pitavastatin was significantly decreased by 81.4  %(95 % CI, 75.0–87.7 %, p < 0.001) compared with non co-treatment of rifampin. Meanwhile, rifampin decreased the t1/2 of pitavastatin by 38.8 % (95 % CI, 18.2–59.4 %, p < 0.001)"	"38.8"	"Percent"	"Decrease"	"Co-treatment of rifampin significantly increased the Cmax of pitavastatin by 819.2 % (95 % C I, 515.4–1123.0 %, p < 0.001) and the AUC(0–48 h) by 573.5 % (95 % CI, 373.3–773.7 %, p < 0.001). Co-treating with rifampin, the CL/F of pitavastatin was significantly decreased by 81.4  %(95 % CI, 75.0–87.7 %, p < 0.001) compared with non co-treatment of rifampin. Meanwhile, rifampin decreased the t1/2 of pitavastatin by 38.8 % (95 % CI, 18.2–59.4 %, p < 0.001)"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVmXPW8J1_rzbHfMC-RQ"
"http://localhost/elsevier/elsevier10456002.html"	"annotat4@gmail.com"	"CsA_interact with_lovastatin"	"The three groups taking CsA had a significantly higher AUC0–8 of lovastatin than the other two (Table 2)."	"DDI clinical trial"	"interact with"	"CsA"	"lovastatin"	"drug1"	""	""	"supports"	"29"	"Lovastatin plasma levels was studied in five groups of patients: (1) six heart and (2) five kidney transplant recipients receiving triple immunosuppressive regimen with CsA, prednisolone, and azathioprine; (3) five kidney transplant recipients receiving prednisolone and azathioprine; (4) five patients with psoriasis treated with CsA monotherapy; and (5) eight hypercholesterolemic “control” patients."	"273"	"UNK"	"UNK"	"Daily"	""	"10"	""	""	""	""	"UNK"	"10"	"QD"	""	"6.73"	"UNK"	"Increase"	"Table 2.
        Plasma AUC0–8 of Lovastatin Among the Five Groups legend"	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVlPHWd71_rzbHfMC-N7"
"http://localhost/elsevier/elsevier10456002.html"	"annotat4@gmail.com"	"CsA_interact with_lovastatin"	"The three groups taking CsA had a significantly higher AUC0–8 of lovastatin than the other two (Table 2)."	"DDI clinical trial"	"interact with"	"CsA"	"lovastatin"	"drug1"	""	""	"supports"	"29"	"Lovastatin plasma levels was studied in five groups of patients: (1) six heart and (2) five kidney transplant recipients receiving triple immunosuppressive regimen with CsA, prednisolone, and azathioprine; (3) five kidney transplant recipients receiving prednisolone and azathioprine; (4) five patients with psoriasis treated with CsA monotherapy; and (5) eight hypercholesterolemic “control” patients."	"230"	"UNK"	"UNK"	"Daily"	""	"10"	""	""	""	""	"UNK"	"10"	"QD"	""	"4.23"	"UNK"	"Increase"	"Table 2.
        Plasma AUC0–8 of Lovastatin Among the Five Groups legend"	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVlPHWd71_rzbHfMC-N7"
"http://localhost/elsevier/elsevier10456002.html"	"annotat4@gmail.com"	"CsA_interact with_lovastatin"	"The three groups taking CsA had a significantly higher AUC0–8 of lovastatin than the other two (Table 2)."	"DDI clinical trial"	"interact with"	"CsA"	"lovastatin"	"drug1"	""	""	"supports"	"29"	"Lovastatin plasma levels was studied in five groups of patients: (1) six heart and (2) five kidney transplant recipients receiving triple immunosuppressive regimen with CsA, prednisolone, and azathioprine; (3) five kidney transplant recipients receiving prednisolone and azathioprine; (4) five patients with psoriasis treated with CsA monotherapy; and (5) eight hypercholesterolemic “control” patients."	"290"	"UNK"	"UNK"	"Daily"	""	"10"	""	""	""	""	"UNK"	"10"	"UNK"	""	"4.23"	"UNK"	"Increase"	"Table 2.
        Plasma AUC0–8 of Lovastatin Among the Five Groups legend"	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVlPHWd71_rzbHfMC-N7"
"http://localhost/wiley/wiley16198653.html"	"rdb20@pitt.edu"	"pitavastatin_substrate of_OATP1B1"	"OATP1B1 variant haplotypes were found to have a significant effect on the pharmacokinetics of pitavastatin. These results suggest that the *15 allele is associated with decreased pitavastatin uptake from blood into hepatocytes and that OATP1B1 genetic polymorphisms have no effect on the pharmacokinetics of pitavastatin lactone."	"Phenotype clinical study"	"substrate of"	"pitavastatin"	""	""	"OATP1B1"	""	"supports"	"24"	"Twenty-four healthy, unrelated Korean male subjects were enrolled in a PK study"	""	""	""	""	""	""	"Genotype"	"UNK"	""	"Asian"	""	""	""	""	"1.8"	"Fold"	"Increase"	"Mean dose-normalized AUC and Cmax values in genotype group 3 (OATP1B1*15/*1a or OATP1B1*15/*1b) were 68.1 ng · h · mL−1 · mg−1 and 29.4 ng · mL−1 · mg−1, respectively, which were 1.8- and 2.2-fold higher than those values (38.8 ng · h · mL−1 · mg−1 and 13.2 ng · mL−1 · mg−1, respectively) in group 1 (OATP1B1*1b/*1b) (Table II and Fig 3)"	"2.2"	"Fold"	"Increase"	"Mean dose-normalized AUC and Cmax values in genotype group 3 (OATP1B1*15/*1a or OATP1B1*15/*1b) were 68.1 ng · h · mL−1 · mg−1 and 29.4 ng · mL−1 · mg−1, respectively, which were 1.8- and 2.2-fold higher than those values (38.8 ng · h · mL−1 · mg−1 and 13.2 ng · mL−1 · mg−1, respectively) in group 1 (OATP1B1*1b/*1b) (Table II and Fig 3)"	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVlRjOQq1_rzbHfMC-OW"
"http://localhost/elsevier/elsevier9726762.html"	"rdb20@pitt.edu"	"gemfibrozil_interact with_warfarin"	"The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil."	"Case Report"	"interact with"	"gemfibrozil"	"warfarin"	"drug1"	""	""	""	""	""	"1200"	"UNK"	"35"	"Daily"	""	"7.5"	""	""	""	""	"UNK"	"1095"	"Daily"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|Yes|Yes|Yes|NA|UNK/NA|No|UNK/NA|Yes|NA"	"External"	"01/02/2017"	6	""	""	""	"AVlVZaNd1_rzbHfMC-O7"
"http://localhost/elsevier/elsevier15883150.html"	"annotat1@gmail.com"	"linezolid_interact with_fluoxetine"	"We present a case of suspected serotonin syndrome caused by the administration of linezolid 18 days after the discontinuation of fluoxetine. It presents the possibility of this antibiotic interacting with norfluoxetine (fluoxetine’s active metabolite), an interaction not previously recognized"	"Case Report"	"interact with"	"linezolid"	"fluoxetine"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|Yes|Yes|Yes|NA|UNK/NA|No|UNK/NA|NA|NA"	"External"	"12/31/2016"	5	""	""	""	"AVlUKc5B1_rzbHfMC-Ou"
"http://localhost/elsevier/elsevier9468088.html"	"annotat4@gmail.com"	"atorvastatin_interact with_gemfibrozil"	"The following report describes a case of rhabdomyolysis that occurred in an acutely ill patient who was taking atorvastatin in combination with gemfibrozil."	"Case Report"	"interact with"	"atorvastatin"	"gemfibrozil"	"drug2"	""	""	""	""	""	"10"	"Oral"	"UNK"	"BID"	""	"600"	""	""	""	""	"Oral"	"Unk"	"BID"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|Yes|Yes|Yes|NA|UNK/NA|Yes|UNK/NA|Yes|NA"	"External"	"12/30/2016"	4	""	""	""	"AVlOfjyh1_rzbHfMC-Nj"
"http://localhost/elsevier/elsevier21601733.html"	"annotat4@gmail.com"	"warfarin_interact with_quetiapine"	"atient with dementia who developed multiple intracerebral hemorrhages (ICHs) 3 days after the addition of quetiapine to his stable warfarin regimen."	"Case Report"	"interact with"	"warfarin"	"quetiapine"	"drug2"	""	""	""	""	""	"3.75"	"Oral"	"365"	"Daily"	""	"12.5"	""	""	""	""	"UNK"	"3"	"Daily"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|UNK|Yes|Yes|NA|UNK/NA|Yes|UNK/NA|Yes|NA"	"External"	"12/30/2016"	3	""	""	""	"AVlODABH1_rzbHfMC-NN"
"http://localhost/elsevier/elsevier20633751.html"	"annotat5@gmail.com"	"quetiapine_interact with_valproate"	"Sodium valproate 1000 mg/day and quetiapine 50 mg/day were initially prescribed, and the dosage of quetiapine was titrated up to 300 mg/day gradually over 3 weeks. At 300 mg/day, the patient became confused, and auditory and visual hallucinations were noted. These symptoms fluctuated over the course of a day. He was diagnosed with delirium"	"Case Report"	"interact with"	"quetiapine"	"valproate"	"drug1"	""	""	""	""	""	"300"	"UNK"	"UNK"	"Daily"	""	"1000"	""	""	""	""	"UNK"	"UNK"	"Daily"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|UNK|UNK/NA|Yes|NA|UNK/NA|Yes|UNK/NA|NA|NA"	"External"	"12/31/2016"	1	""	""	""	"AVlT0fsQ1_rzbHfMC-On"
"http://localhost/elsevier/elsevier20633751.html"	"annotat5@gmail.com"	"quetiapine_interact with_valproate"	"The night after the initiation of quetiapine treatment, the patient became abruptly confused, disoriented with visual hallucinations, and more agitated. The disorientation and confusion fluctuated over the course of a day. At this time, the plasma level of valproate was 103 μg/ml. Neurologic, physical and laboratory examinations did not reveal any pathology. She met the diagnostic criteria for delirium according to the Diagnostic and Statistical Manual for Mental Disorders, Fourth edition. After discontinuation of quetiapine and the addition of 5 mg/day of oral haloperidol, the delirium fully resolved within 2 days, but mania persisted"	"Case Report"	"interact with"	"quetiapine"	"valproate"	"drug1"	""	""	""	""	""	"100"	"UNK"	"UNK"	"Daily"	""	"1000"	""	""	""	""	"UNK"	"UNK"	"Daily"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|UNK|UNK/NA|Yes|NA|UNK/NA|Yes|UNK/NA|NA|NA"	"External"	"12/31/2016"	1	""	""	""	"AVlTvg0k1_rzbHfMC-Ok"
"http://localhost/elsevier/elsevier15935493.html"	"rdb20@pitt.edu"	"ciprofloxacin_interact with_olanzapine"	"In the present case report, an elderly woman receiving a long-term medication with azathioprine, olanzapine and valsartan developed a marked QT interval prolongation after intravenous administration of ciprofloxacin."	"Case Report"	"interact with"	"ciprofloxacin"	"olanzapine"	"drug1"	""	""	""	""	""	"800"	"IV"	"UNK"	"Daily"	""	"10"	""	""	""	""	"UNK"	"UNK"	"Daily"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"NA|Yes|Yes|Yes|NA|UNK/NA|UNK/NA|UNK/NA|Yes|NA"	"External"	"12/31/2016"	4	""	""	""	"AVlRgg3W1_rzbHfMC-OS"
"http://localhost/elsevier/elsevier16005413.html"	"annotat5@gmail.com"	"escitalopram_interact with_oxycodone"	"She was on escitalopram 10 mg per day and extended release oxycodone 20 mg twice daily. Approximately 5 weeks prior to this episode, her extended release oxycodone dose had been doubled. Her evaluation in the emergency room, including a computed tomography (CT) scan of the head, was normal. She was administered intravenous lorazepam, and her escitalopram and oxycodone were stopped. In less than a day, her myoclonic jerks resolved and her blood pressure returned to baseline. Later, her prior dose of oxycodone (20 mg twice daily) was restarted, but not her escitalopram. Neither myoclonus nor blood pressure elevation recurred."	"Case Report"	"interact with"	"escitalopram"	"oxycodone"	"drug1"	""	""	""	""	""	"10"	"UNK"	"UNK"	"QD"	""	"20"	""	""	""	""	"UNK"	"UNK"	"BID"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"No|Yes|No|Yes|NA|UNK/NA|No|UNK/NA|NA|NA"	"External"	"12/30/2016"	1	""	""	""	"AVlPamGQ1_rzbHfMC-OH"
"http://localhost/elsevier/elsevier16005413.html"	"annotat5@gmail.com"	"hydrocodone_interact with_escitalopram"	"Her antidepressant was changed to escitalopram at 10 mg per day. When she was seen a few weeks later, she complained of seeing strangers in her room, especially at night, which was extremely frightening to her. A diagnosis of complex visual hallucinations was made after ruling out acute infectious and metabolic problems. At the same visit, her hydrocodone was discontinued, as her pain had improved. On a routine visit a month later, she reported that, to her great relief, she was no longer experiencing the visual hallucinations"	"Case Report"	"interact with"	"hydrocodone"	"escitalopram"	"drug1"	""	""	""	""	""	"10"	"UNK"	"UNK"	"QD"	""	"10"	""	""	""	""	"UNK"	"UNK"	"QD"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"No|Yes|No|Yes|NA|UNK/NA|No|UNK/NA|NA|NA"	"External"	"12/30/2016"	1	""	""	""	"AVlPhblW1_rzbHfMC-OL"
"http://localhost/elsevier/elsevier16005413.html"	"annotat5@gmail.com"	"tramadol_interact with_mirtazapine"	"85-year-old female LTC resident, was seen for recurrent episodes of lethargy, confusion, hypotension, bronchospasm, and hypoxia. No associated motor symptoms were noted. Evaluations were negative for infection, metabolic derangements, or pulmonary embolus. Review of her medications showed that she was on mirtazapine 22.5 mg once daily, which was begun 4 days prior to the episode and tramadol 100 mg 3 times daily, which was started several months earlier."	"Case Report"	"interact with"	"tramadol"	"mirtazapine"	"drug1"	""	""	""	""	""	"100"	"UNK"	"UNK"	"TID"	""	"22.5"	""	""	""	""	"UNK"	"UNK"	"QD"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|Yes|Yes|Yes|NA|UNK/NA|UNK/NA|UNK/NA|NA|NA"	"External"	"12/30/2016"	4	""	""	""	"AVlPkqEp1_rzbHfMC-OO"
"http://localhost/elsevier/elsevier16005413.html"	"annotat5@gmail.com"	"Sertraline_interact with_oxycodone"	"Probable serotonin syndrome precipitated by the increase in opiate dose was considered. Sertraline was rapidly tapered off along with a reduction in her oxycodone dose. She showed dramatic improvement within 2 days and had no tremors, myoclonus, or rigidity. She was able to walk with her front-wheel walker and her agitation improved"	"Case Report"	"interact with"	"Sertraline"	"oxycodone"	"drug1"	""	""	""	""	""	"150"	"UNK"	"UNK"	"QD"	""	"20"	""	""	""	""	"UNK"	"UNK"	"BID"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"No|Yes|No|Yes|NA|UNK/NA|No|UNK/NA|NA|NA"	"External"	"12/30/2016"	1	""	""	""	"AVlPFtj61_rzbHfMC-N5"
"http://localhost/elsevier/elsevier11959068.html"	"rdb20@pitt.edu"	"delavirdine_interact with_atorvastatin"	"We report a patient who developed acute tubular necrosis caused by severe rhabdomyolysis, which was probably associated with the coadministration of atorvastatin and delavirdine"	"Case Report"	"interact with"	"delavirdine"	"atorvastatin"	"drug1"	""	""	""	""	""	"400"	"UNK"	"1825"	"Daily"	""	"20"	""	""	""	""	"UNK"	"1825"	"Daily"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"NA|Yes|Yes|Yes|NA|UNK/NA|UNK/NA|UNK/NA|Yes|NA"	"External"	"12/31/2016"	4	""	""	""	"AVlRhvWu1_rzbHfMC-OU"
"http://localhost/elsevier/elsevier16005413.html"	"annotat5@gmail.com"	"escitalopram_interact with_oxycodone"	"She was on escitalopram 10 mg per day and extended release oxycodone 20 mg twice daily. Approximately 5 weeks prior to this episode, her extended release oxycodone dose had been doubled. Her evaluation in the emergency room, including a computed tomography (CT) scan of the head, was normal. She was administered intravenous lorazepam, and her escitalopram and oxycodone were stopped. In less than a day, her myoclonic jerks resolved and her blood pressure returned to baseline. Later, her prior dose of oxycodone (20 mg twice daily) was restarted, but not her escitalopram. Neither myoclonus nor blood pressure elevation recurred."	"Case Report"	"interact with"	"escitalopram"	"oxycodone"	""	""	""	""	""	""	"10"	"UNK"	"UNK"	"QD"	""	"20"	""	""	""	""	"UNK"	"UNK"	"BID"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	"Author"	"12/30/2016"	"NA"	""	""	""	"AVlPSIGy1_rzbHfMC-OC"
"http://localhost/elsevier/elsevier16005413.html"	"annotat5@gmail.com"	"escitalopram_interact with_oxycodone"	"She was on escitalopram 10 mg per day and extended release oxycodone 20 mg twice daily. Approximately 5 weeks prior to this episode, her extended release oxycodone dose had been doubled. Her evaluation in the emergency room, including a computed tomography (CT) scan of the head, was normal. She was administered intravenous lorazepam, and her escitalopram and oxycodone were stopped. In less than a day, her myoclonic jerks resolved and her blood pressure returned to baseline. Later, her prior dose of oxycodone (20 mg twice daily) was restarted, but not her escitalopram. Neither myoclonus nor blood pressure elevation recurred."	"Case Report"	"interact with"	"escitalopram"	"oxycodone"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVlPRvOK1_rzbHfMC-OB"
"http://localhost/elsevier/elsevier10456002.html"	"annotat5@gmail.com"	"CsA_interact with_lovastatin"	"The three groups taking CsA had a significantly higher AUC0–8 of lovastatin than the other two (Table 2)."	"DDI clinical trial"	"interact with"	"CsA"	"lovastatin"	"drug1"	""	""	"supports"	"29"	"Lovastatin plasma levels was studied in five groups of patients: (1) six heart and (2) five kidney transplant recipients receiving triple immunosuppressive regimen with CsA, prednisolone, and azathioprine; (3) five kidney transplant recipients receiving prednisolone and azathioprine; (4) five patients with psoriasis treated with CsA monotherapy; and (5) eight hypercholesterolemic “control” patients."	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVlOMVRo1_rzbHfMC-NZ"
"http://localhost/elsevier/elsevier16005413.html"	"annotat5@gmail.com"	"Sertraline_interact with_oxycodone"	"Probable serotonin syndrome precipitated by the increase in opiate dose was considered. Sertraline was rapidly tapered off along with a reduction in her oxycodone dose. She showed dramatic improvement within 2 days and had no tremors, myoclonus, or rigidity. She was able to walk with her front-wheel walker and her agitation improved."	"Case Report"	"interact with"	"Sertraline"	"oxycodone"	"drug2"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"No|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	"Author"	"12/29/2016"	"NA"	""	""	""	"AVlKpUgI1_rzbHfMC-NF"
"http://localhost/wiley/wiley16882112.html"	"rdb20@pitt.edu"	"lithium_interact with_venlafaxine"	"We report a case of the serotonin syndrome during treatment with lithium and venlafaxine, an antidepressant with a dual selective re-uptake inhibition mechanism, and review the literature for similar cases."	"Case Report"	"interact with"	"lithium"	"venlafaxine"	"drug1"	""	""	""	""	""	"400"	"Oral"	"UNK"	"Daily"	""	"150"	""	""	""	""	"Oral"	"UNK"	"Daily"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"Yes|Yes|Yes|Yes|NA|UNK/NA|UNK/NA|Yes|Yes|NA"	"External"	"12/28/2016"	6	""	""	""	"AVlGe1JX1_rzbHfMC-M0"
"http://localhost/wiley/wiley18784280.html"	"rdb20@pitt.edu"	"Aliskiren_substrate of_atorvastatin"	"Aliskiren AUCτwas significantly increased by coadministration with atorvastatin (by 47%, P < .001) or ketoconazole (by 76%, P < .001) through mechanisms most likely involving transporters such as P-glycoprotein and organic anion-transporting peptide and possibly through metabolic pathways such as CYP3A4 in the gut wall. These results indicate that aliskiren is a substrate for but not an inhibitor of P-glycoprotein."	"DDI clinical trial"	"substrate of"	"Aliskiren"	"atorvastatin"	""	"P_Glycoprotein"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVlGYcjD1_rzbHfMC-Mu"
"http://localhost/wiley/wiley17460607.html"	"rdb20@pitt.edu"	"pitavastatin_substrate of_OATP1B1"	"To investigate the contribution of genetic polymorphisms of SLCO1B1 and ABCG2 to the pharmacokinetics of a dual substrate, pitavastatin, 2 mg of pitavastatin was administered to 38 healthy volunteers and pharmacokinetic parameters were compared among the following groups: 421C/C*1b/*1b (group 1), 421C/C*1b/*15 (group 2), 421C/C*15/*15 and 421C/A*15/*15 (group 3), 421C/A*1b/*1b (group 4), 421A/A*1b/*1b (group 5), and 421C/A*1b/*15 (group 6). In SLCO1B1, pitavastatin area under plasma concentration–time curve from 0 to 24 h (AUC0–24) for groups 1, 2, and 3 was 81.1±18.1, 144±32, and 250±57 ng h/ml, respectively, with significant differences among all three groups. In contrast to SLCO1B1, AUC0–24 in groups 1, 4, and 5 was 81.1±18.1, 96.7±35.4, and 78.2±8.2 ng h/ml, respectively."	"Phenotype clinical study"	"substrate of"	"pitavastatin"	""	""	"OATP1B1"	""	"supports"	"38"	"After approval by the Ethics Review Board of Kyushu University and Kyushu Clinical Pharmacology Research Clinic, 38 healthy male volunteers (age, 20–32 years; weight, 52.4–72.4 kg) gave written informed consent to participate in the study. None had taken any drugs for at least 1 week before the study. Each subject was physically normal and had no antecedent history of significant medical illness or hypersensitivity to any drugs, and each had a body mass index between 17.6 and 26.4 kg/m2. Their health status was judged to be normal on the basis of a physical examination with screening of blood chemistry, a complete blood count and urinalysis, and an electrocardiogram just before the study."	"2"	"Oral"	"1"	"SD"	""	""	"Genotype"	"UNK"	"Extensive Metabolizer"	"Asian"	""	""	""	""	"1.7"	"Fold"	"Increase"	"Table 1. Pharmacokinetic parameters of pitavastatin and its lactone form in each genotyping group"	"2.27"	"Fold"	"Increase"	"Table 1. Pharmacokinetic parameters of pitavastatin and its lactone form in each genotyping group"	"44.2"	"Percent"	"Decrease"	"Table 1. Pharmacokinetic parameters of pitavastatin and its lactone form in each genotyping group"	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVlGQmlg1_rzbHfMC-Mn"
"http://localhost/wiley/wiley17460607.html"	"rdb20@pitt.edu"	"pitavastatin_substrate of_OATP1B1"	"To investigate the contribution of genetic polymorphisms of SLCO1B1 and ABCG2 to the pharmacokinetics of a dual substrate, pitavastatin, 2 mg of pitavastatin was administered to 38 healthy volunteers and pharmacokinetic parameters were compared among the following groups: 421C/C*1b/*1b (group 1), 421C/C*1b/*15 (group 2), 421C/C*15/*15 and 421C/A*15/*15 (group 3), 421C/A*1b/*1b (group 4), 421A/A*1b/*1b (group 5), and 421C/A*1b/*15 (group 6). In SLCO1B1, pitavastatin area under plasma concentration–time curve from 0 to 24 h (AUC0–24) for groups 1, 2, and 3 was 81.1±18.1, 144±32, and 250±57 ng h/ml, respectively, with significant differences among all three groups. In contrast to SLCO1B1, AUC0–24 in groups 1, 4, and 5 was 81.1±18.1, 96.7±35.4, and 78.2±8.2 ng h/ml, respectively."	"Phenotype clinical study"	"substrate of"	"pitavastatin"	""	""	"OATP1B1"	""	"supports"	"38"	"After approval by the Ethics Review Board of Kyushu University and Kyushu Clinical Pharmacology Research Clinic, 38 healthy male volunteers (age, 20–32 years; weight, 52.4–72.4 kg) gave written informed consent to participate in the study. None had taken any drugs for at least 1 week before the study. Each subject was physically normal and had no antecedent history of significant medical illness or hypersensitivity to any drugs, and each had a body mass index between 17.6 and 26.4 kg/m2. Their health status was judged to be normal on the basis of a physical examination with screening of blood chemistry, a complete blood count and urinalysis, and an electrocardiogram just before the study."	"2"	"Oral"	"1"	"SD"	""	""	"Genotype"	"UNK"	"Poor Metabolizer"	"Asian"	""	""	""	""	"3.08"	"Fold"	"Increase"	"Table 1. Pharmacokinetic parameters of pitavastatin and its lactone form in each genotyping group"	"4.13"	"Fold"	"Increase"	"Table 1. Pharmacokinetic parameters of pitavastatin and its lactone form in each genotyping group"	"65.1"	"Percent"	"Decrease"	"Table 1. Pharmacokinetic parameters of pitavastatin and its lactone form in each genotyping group"	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"AVlGQmlg1_rzbHfMC-Mn"
"http://localhost/wiley/wiley17192770.html"	"rdb20@pitt.edu"	"Rifampin_interact with_atorvastatin"	"Plasma concentrations of atorvastatin and metabolites were above the limits of quantitation for up to 24 h after dosing. Rifampin significantly increased the total area under the plasma concentration-time curve (AUC) of atorvastatin acid by 6.8±2.4-fold and that of 2-hydroxy-atorvastatin acid and 4-hydroxy-atorvastatin acid by 6.8±2.5- and 3.9±2.4-fold, respectively. The AUC values of the lactone forms of atorvastatin, 2-hydroxy-atorvastatin and 4-hydroxy-atorvastatin, were also significantly increased, but to a lower extent. An intravenous dose of rifampin substantially increased the plasma concentrations of atorvastatin and its acid and lactone metabolites."	"DDI clinical trial"	"interact with"	"Rifampin"	"atorvastatin"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVlGPD_j1_rzbHfMC-Ml"
"http://localhost/wiley/wiley16027406.html"	"rdb20@pitt.edu"	"fenofibrate_interact with_pravastatin"	"Coadministration of fenofibrate had modest effects on pravastatin and 3α-hydroxy-iso-pravastatin systemic exposures (AUC). Increases in pravastatin systemic exposures (19%-28%, on average) and 3α-hydroxy-iso-pravastatin systemic exposures (24%-39%, on average) were observed upon coadministration, but individual changes were variable. Pravastatin and 3α-hydroxy-iso-pravastatin systemic exposures were not statistically significantly different following the 1st and 10th doses of fenofibrate."	"DDI clinical trial"	"interact with"	"fenofibrate"	"pravastatin"	"drug1"	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"AVlGLLiA1_rzbHfMC-Mc"
"http://localhost/wiley/wiley21712498.html"	"annotat2@gmail.com"	"rosuvastatin_interact with_darunavir or ritonavir"	"In contrast to the observed changes in rosuvastatin pharmacokinetics, there were no significant changes apparent in the steady-state pharmacokinetics of darunavir or ritonavir pharmacokinetics in the presence of steady-state dosing of rosuvastatin"	"DDI clinical trial"	"interact with"	"rosuvastatin"	"darunavir or ritonavir"	"drug1"	""	""	"refutes"	"20.00"	"Of 20 participants screened"	"600/100"	"Oral"	"7"	"BID"	""	"10"	""	""	""	""	"Oral"	"7"	"Daily"	""	"unchanged"	"None"	"None"	"In contrast to the observed changes in rosuvastatin pharmacokinetics, there were no significant changes apparent in the steady-state pharmacokinetics of darunavir or ritonavir pharmacokinetics in the presence of steady-state dosing of rosuvastatin"	"unchanged"	"None"	"None"	"In contrast to the observed changes in rosuvastatin pharmacokinetics, there were no significant changes apparent in the steady-state pharmacokinetics of darunavir or ritonavir pharmacokinetics in the presence of steady-state dosing of rosuvastatin"	"unchanged"	"None"	"None"	"In contrast to the observed changes in rosuvastatin pharmacokinetics, there were no significant changes apparent in the steady-state pharmacokinetics of darunavir or ritonavir pharmacokinetics in the presence of steady-state dosing of rosuvastatin"	"unchanged"	"None"	"None"	"In contrast to the observed changes in rosuvastatin pharmacokinetics, there were no significant changes apparent in the steady-state pharmacokinetics of darunavir or ritonavir pharmacokinetics in the presence of steady-state dosing of rosuvastatin"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"49daaa9b-3c96-4f9a-ab63-56a8a7fdecf4"
"http://localhost/PMC/PMC90851.html"	"annotat2@gmail.com"	"Nelfinavir_interact with_atorvastatin"	"Nelfinavir increased the steady-state area under the plasma concentration-time curve during one dosing period (AUCτ) of atorvastatin 74% and the maximum concentration (Cmax) of atorvastatin 122% and increased the AUCτ of simvastatin 505% and the Cmax of simvastatin 517%. Neither atorvastatin nor simvastatin appeared to alter the pharmacokinetics of nelfinavir."	"DDI clinical trial"	"interact with"	"Nelfinavir"	"atorvastatin"	"drug1"	""	""	"supports"	"32.00"	"The 32 enrolled subjects consisted of 12 Caucasians (six males and six females), 15 African Americans (eight males and seven females), and five Hispanics (two males and three females)."	"1250"	"Oral"	"14"	"BID"	""	"10"	""	""	""	""	"Oral"	"28"	"QD"	""	"1.74"	"Fold"	"Increase"	"Pharmacokinetic parameters of atorvastatin and simvastatin"	"2.22"	"Fold"	"Increase"	"Pharmacokinetic parameters of atorvastatin and simvastatin"	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"ad9ebb90-dd73-4a69-9966-dd1ad66f5eb3"
"http://localhost/wiley/wiley15903129.html"	"annotat2@gmail.com"	"paroxetine_interact with_tramadol"	"With paroxetine pretreatment, the area under the plasma concentration-time curve (AUC) of (+)- and (−)-tramadol was increased (37% [P = .001] and 32% [P = .002], respectively), and the corresponding AUCs of (+)- and (−)-M1 were decreased (67% [P = .0004] and 40% [P = .0008], respectively)."	"DDI clinical trial"	"interact with"	"paroxetine"	"tramadol"	"drug1"	""	""	"supports"	"16.00"	"Fourteen male and 2 female healthy, drug-free (except for oral contraceptives) volunteers aged 20 to 30 years participated."	"150"	"Oral"	"1"	"SD"	""	"20"	""	""	""	""	"Oral"	"3"	"Daily"	""	"32"	"Percent"	"Increase"	"Table I. Areas under plasma concentration-time curves of enantiomers of tramadol and metabolite M1"	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"32a286c0-7835-4c2b-b809-19825ac8920c"
"http://localhost/PMC/PMC3769672.html"	"annotat2@gmail.com"	"clarithromycin_interact with_rivaroxaban"	"Co-administration with clarithromycin significantly increased the primary pharmacokinetic parameters of rivaroxaban (Table 2, Figure 1C). Both the mean AUC and Cmax were significantly increased, by 54% (90% CI 44%, 64%) and 40% (90% CI 30%, 52%), respectively, in comparison with rivaroxaban alone."	"DDI clinical trial"	"interact with"	"clarithromycin"	"rivaroxaban"	"drug1"	""	""	"supports"	"16.00"	"A total of 16 subjects were enrolled into the study, with a mean age of 37.6 years (range 24-50 years) and a mean weight of 81.1 ± 12.0 kg."	"10"	"Oral"	"1"	"SD"	""	"500"	""	""	""	""	"Oral"	"4"	"BID"	""	"1.54"	"UNK"	"Increase"	"Co-administration with clarithromycin significantly increased the primary pharmacokinetic parameters of rivaroxaban (Table 2, Figure 1C). Both the mean AUC and Cmax were significantly increased, by 54% (90% CI 44%, 64%) and 40% (90% CI 30%, 52%), respectively, in comparison with rivaroxaban alone."	"1.4"	"UNK"	"Increase"	"Co-administration with clarithromycin significantly increased the primary pharmacokinetic parameters of rivaroxaban (Table 2, Figure 1C). Both the mean AUC and Cmax were significantly increased, by 54% (90% CI 44%, 64%) and 40% (90% CI 30%, 52%), respectively, in comparison with rivaroxaban alone."	"0.65"	"UNK"	"Decrease"	"Co-administration with clarithromycin significantly increased the primary pharmacokinetic parameters of rivaroxaban (Table 2, Figure 1C). Both the mean AUC and Cmax were significantly increased, by 54% (90% CI 44%, 64%) and 40% (90% CI 30%, 52%), respectively, in comparison with rivaroxaban alone."	"unchanged"	"None"	"None"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"dc673c2c-6814-4129-983b-33e077f3deb8"
"http://localhost/PMC/PMC3769672.html"	"annotat2@gmail.com"	"erythromycin_interact with_rivaroxaban"	"Co-administration with steady-state erythromycin significantly increased the pharmacokinetics of rivaroxaban (Table 2, Figure 1D). The mean AUC and Cmax both significantly increased (by 34% [90% CI 23%, 46%] and 38% [90% CI 21%, 48%], respectively) compared with rivaroxaban alone."	"DDI clinical trial"	"interact with"	"erythromycin"	"rivaroxaban"	"drug1"	""	""	"supports"	"16.00"	"A total of 16 subjects were enrolled into the study and were valid for the safety analysis."	"10"	"Oral"	"1"	"SD"	""	"500"	""	""	""	""	"Oral"	"4"	"TID"	""	"1.34"	"UNK"	"Increase"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"1.38"	"UNK"	"Increase"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"0.75"	"Fold"	"Decrease"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"unchanged"	"None"	"None"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"b3c39ef1-624a-4157-b6b9-0afc25960e51"
"http://localhost/PMC/PMC3187007.html"	"annotat2@gmail.com"	"telaprevir_interact with_amlodipine"	"Based on the ratio of the LS means, the mean Cmax and AUC0-∞ of amlodipine were increased 1.27-fold and 2.79-fold, respectively, by the coadministration of telaprevir (Table 1)"	"DDI clinical trial"	"interact with"	"telaprevir"	"amlodipine"	"drug1"	""	""	"supports"	"21.00"	"Twenty-one healthy male (n = 15) and female (n = 6) volunteers were enrolled at the Covance Clinical Research Unit, Inc., Daytona Beach, FL."	"750"	"Oral"	"16"	"Q8"	""	"5"	""	""	""	""	"Oral"	"1"	"SD"	""	"2.79"	"Fold"	"Increase"	"Based on the ratio of the LS means, the mean Cmax and AUC0-∞ of amlodipine were increased 1.27-fold and 2.79-fold, respectively, by the coadministration of telaprevir (Table 1)"	"1.27"	"Fold"	"Increase"	"Based on the ratio of the LS means, the mean Cmax and AUC0-∞ of amlodipine were increased 1.27-fold and 2.79-fold, respectively, by the coadministration of telaprevir (Table 1)"	"67.6"	"Percent"	"Decrease"	"The mean t1/2 of amlodipine increased from 41.3 h to 95.1 h, and the mean apparent clearance (CL/F) decreased from 38.0 liters/h to 12.3 liters/h."	"2.3"	"Fold"	"Increase"	"The mean t1/2 of amlodipine increased from 41.3 h to 95.1 h, and the mean apparent clearance (CL/F) decreased from 38.0 liters/h to 12.3 liters/h."	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"b2705a98-b3e6-4722-837d-9652bf0f5ed6"
"http://localhost/PMC/PMC3769672.html"	"annotat2@gmail.com"	"fluconazole_interact with_rivaroxaban"	"Co-administration with fluconazole significantly increased the primary pharmacokinetic parameters of rivaroxaban (Table 2, Figure 1E). Both the mean AUC and mean Cmax increased (by 42% [90% CI 29%, 56%] and 28% [90% CI 12%, 47%], respectively) in comparison with rivaroxaban alone."	"DDI clinical trial"	"interact with"	"fluconazole"	"rivaroxaban"	"drug1"	""	""	"supports"	"14.00"	"A total of 14 subjects were enrolled into the study, with a mean age of 33.8 years (range 24-53 years) and a mean weight of 83.7 ± 9.4 kg"	"20"	"Oral"	"1"	"SD"	""	"400"	""	""	""	""	"Oral"	"6"	"Daily"	""	"1.42"	"UNK"	"Increase"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"1.28"	"UNK"	"Increase"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"0.71"	"Fold"	"Decrease"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"unchanged"	"None"	"None"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"12efc3a9-1924-4a5a-90da-2d120cebeb47"
"http://localhost/wiley/wiley21712498.html"	"annotat2@gmail.com"	"darunavir/ritonavir_interact with_rosuvastatin"	"As noted here, the main findings of our study are that the concomitant administration of darunavir/ritonavir in HIV-seronegative healthy volunteers caused a marked change in the systemic exposure of rosuvastatin. The geometric mean steady-state Cmax and AUC0–24 h of rosuvastatin increased by an average of 2.4-fold and 1.5-fold, respectively."	"DDI clinical trial"	"interact with"	"darunavir/ritonavir"	"rosuvastatin"	"drug1"	""	""	"supports"	"20.00"	"Of 20 participants screened"	"10"	"Oral"	"7"	"Daily"	""	"600/100"	""	""	""	""	"Oral"	"7"	"BID"	""	"1.5"	"Fold"	"Increase"	"Table I.  Pharmacokinetics of Rosuvastatin"	"2.4"	"Fold"	"Increase"	"Table I.  Pharmacokinetics of Rosuvastatin"	"0.7"	"Fold"	"Decrease"	"Table I.  Pharmacokinetics of Rosuvastatin"	"unchanged"	"None"	"None"	"Table I.  Pharmacokinetics of Rosuvastatin"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"ba7d0f83-07f2-4409-8817-4bc4774e11ea"
"http://localhost/wiley/wiley17442686.html"	"annotat2@gmail.com"	"clopidogrel_interact with_fluvastatin"	"Compared to treatment with fluvastatin alone, fluvastatin AUC was similar and Cmax increased marginally (15.7%) with concomitant treatment with clopidogrel."	"DDI clinical trial"	"interact with"	"clopidogrel"	"fluvastatin"	"drug1"	""	""	"refutes"	"30.00"	"30 healthy male volunteers were enrolled to ensure that at least 24 subjects would complete the study."	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"a35990b3-3140-4476-94af-943ae8ee8bbd"
"http://localhost/wiley/wiley17301736.html"	"annotat2@gmail.com"	"arone_interact with_simvastatin"	"Amiodarone increased simvastatin acid AUC (area under the plasma concentration–time curve)0–24 h, peak plasma concentration (Cmax), and t1/2 by 73% (P=0.02), 100% (P=0.02), and 48% (P=0.06), respectively, whereas it did not significantly alter pravastatin pharmacokinetics."	"DDI clinical trial"	"interact with"	"arone"	"simvastatin"	"drug1"	""	""	"supports"	"12.00"	". Twelve white occidental healthy volunteers (seven male and five female subjects) aged 19–43 years were enrolled in this study."	"40"	"Oral"	"2"	"SD"	""	"400"	""	""	""	""	"Oral"	"3"	"SD"	""	"155"	"Percent"	"Increase"	"Amiodarone significantly increased the mean AUC0–24 h of both the parent simvastatin lactone (by 73% P=0.02) and of simvastatin acid (by 78% P=0.02) (Table 1 and Figure 2). The Cmax of simvastatin acid was increased by 100% by amiodarone (P=0.02). Amiodarone had no significant effect on the t1/2 of simvastatin and a borderline effect on the t1/2 of simvastatin acid (P=0.06).Table 1. Pharmacokinetics of simvastatin and pravastatin in the absence and presence of amiodarone CmaxT1/2AUC0–24 h (ng ml−1)(h)(ng h ml−1)AUC, area under the plasma concentration–time curve; CI, confidence interval; Cmax, peak plasma concentration; T1/2, half-life.Results are expressed as mean±SD; *P=0.02 vs in the absence of amiodarone. The point estimates and their confidence intervals refer to 90% confidence intervals about the geometric mean ratio (point estimates) of the observed pharmacokinetic measures with amiodarone and without amiodarone.Simvastatin acid2.4±1.35.0±1.523.1±12.9Simvastatin acid+amiodarone4.3±3.1*7.4±3.740.7±28.5*Point estimate (90% CI)156% (109–223%) 154% (109–216%)    Simvastatin lactone11.6±6.37.9±3.640.6±13.6Simvastatin lactone+amiodarone20.0±16.810.0±5.571.1±49.8*Point estimate (90% CI)150% (100–223%) 155% (109–227%)"	"150"	"Percent"	"UNK"	"Amiodarone significantly increased the mean AUC0–24 h of both the parent simvastatin lactone (by 73% P=0.02) and of simvastatin acid (by 78% P=0.02) (Table 1 and Figure 2). The Cmax of simvastatin acid was increased by 100% by amiodarone (P=0.02). Amiodarone had no significant effect on the t1/2 of simvastatin and a borderline effect on the t1/2 of simvastatin acid (P=0.06).Table 1. Pharmacokinetics of simvastatin and pravastatin in the absence and presence of amiodarone CmaxT1/2AUC0–24 h (ng ml−1)(h)(ng h ml−1)AUC, area under the plasma concentration–time curve; CI, confidence interval; Cmax, peak plasma concentration; T1/2, half-life.Results are expressed as mean±SD; *P=0.02 vs in the absence of amiodarone. The point estimates and their confidence intervals refer to 90% confidence intervals about the geometric mean ratio (point estimates) of the observed pharmacokinetic measures with amiodarone and without amiodarone.Simvastatin acid2.4±1.35.0±1.523.1±12.9Simvastatin acid+amiodarone4.3±3.1*7.4±3.740.7±28.5*Point estimate (90% CI)156% (109–223%) 154% (109–216%)    Simvastatin lactone11.6±6.37.9±3.640.6±13.6Simvastatin lactone+amiodarone20.0±16.810.0±5.571.1±49.8*Point estimate (90% CI)150% (100–223%) 155% (109–227%)"	""	""	""	""	"unchanged"	"None"	"None"	"Amiodarone significantly increased the mean AUC0–24 h of both the parent simvastatin lactone (by 73% P=0.02) and of simvastatin acid (by 78% P=0.02) (Table 1 and Figure 2). The Cmax of simvastatin acid was increased by 100% by amiodarone (P=0.02). Amiodarone had no significant effect on the t1/2 of simvastatin and a borderline effect on the t1/2 of simvastatin acid (P=0.06).Table 1. Pharmacokinetics of simvastatin and pravastatin in the absence and presence of amiodarone CmaxT1/2AUC0–24 h (ng ml−1)(h)(ng h ml−1)AUC, area under the plasma concentration–time curve; CI, confidence interval; Cmax, peak plasma concentration; T1/2, half-life.Results are expressed as mean±SD; *P=0.02 vs in the absence of amiodarone. The point estimates and their confidence intervals refer to 90% confidence intervals about the geometric mean ratio (point estimates) of the observed pharmacokinetic measures with amiodarone and without amiodarone.Simvastatin acid2.4±1.35.0±1.523.1±12.9Simvastatin acid+amiodarone4.3±3.1*7.4±3.740.7±28.5*Point estimate (90% CI)156% (109–223%) 154% (109–216%)    Simvastatin lactone11.6±6.37.9±3.640.6±13.6Simvastatin lactone+amiodarone20.0±16.810.0±5.571.1±49.8*Point estimate (90% CI)150% (100–223%) 155% (109–227%)"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"ab76ea82-e07e-45cf-9fb4-4bfe972bc196"
"http://localhost/PMC/PMC3187007.html"	"annotat2@gmail.com"	"telaprevir_interact with_atorvastatin"	"Upon the coadministration of telaprevir with a single dose of amlodipine-atorvastatin, the atorvastatin AUC0-∞ increased 7.88-fold and the atorvastatin Cmax increased 10.6-fold."	"DDI clinical trial"	"interact with"	"telaprevir"	"atorvastatin"	"drug1"	""	""	"supports"	"21.00"	"Twenty-one healthy male (n = 15) and female (n = 6) volunteers were enrolled at the Covance Clinical Research Unit, Inc., Daytona Beach, FL."	"20"	"Oral"	"16"	"Q8"	""	"20"	""	""	""	""	"Oral"	"1"	"SD"	""	"7.88"	"Fold"	"Increase"	"Based on the ratio of the LS means, the mean Cmax and the AUC0-∞ were markedly increased 10.6-fold and 7.88-fold, respectively, by the coadministration of telaprevir (Table 1)."	"10.6"	"Fold"	"Increase"	"Based on the ratio of the LS means, the mean Cmax and the AUC0-∞ were markedly increased 10.6-fold and 7.88-fold, respectively, by the coadministration of telaprevir (Table 1)."	"87.8"	"Percent"	"Decrease"	"The mean apparent clearance (CL/F) decreased from 685 liters/h to 83.8 liters/h. The mean (SD) t1/2 decreased from 9.44 (2.64) h to 6.75 (1.55) h with telaprevir coadministration; the difference in t1/2 was not statistically significant."	"28.5"	"Percent"	"Decrease"	"The mean apparent clearance (CL/F) decreased from 685 liters/h to 83.8 liters/h. The mean (SD) t1/2 decreased from 9.44 (2.64) h to 6.75 (1.55) h with telaprevir coadministration; the difference in t1/2 was not statistically significant."	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"9355f2bb-d0c9-4316-890b-f31a10ab57f6"
"http://localhost/PMC/PMC2686069.html"	"annotat2@gmail.com"	"ambrisentan_interact with_S-warfarin"	"The concentration–time profiles of both warfarin enantiomers were virtually superimposable in the presence (day 13) or absence (day 1) of ambrisentan. Following multiple doses of ambrisentan, the observed mean AUC0–last values for R-and S-warfarin increased by 4.7% (GMR 104.7; 90% CI 101.7, 107.7) and 1.6% (101.6; 90% CI 98.4, 105.0), respectively, and mean Cmax values decreased for both enantiomers by 8.4% (91.6; 90% CI 86.2, 97.4) and 10.1% (93.0; 90% CI 90.8, 95.3), respectively (Table 1)."	"DDI clinical trial"	"interact with"	"ambrisentan"	"S-warfarin"	"drug1"	""	""	"refutes"	"22.00"	"In this open-label cross-over study, 22 healthy subjects received a single dose of racemic warfarin 25 mg alone and after 8 days of ambrisentan 10 mg once daily"	"25"	"Oral"	"1"	"SD"	""	"10"	""	""	""	""	"Oral"	"12"	"Daily"	""	"unchanged"	"None"	"None"	"Effect of ambrisentan on R-and S-warfarin pharmacokinetics"	"89.9"	"Fold"	"Decrease"	"Effect of ambrisentan on R-and S-warfarin pharmacokinetics"	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"391f9e6d-e272-4f4e-8afb-c25ef104508a"
"http://localhost/PMC/PMC2764168.html"	"annotat2@gmail.com"	"atorvastatin_interact with_TPV/r"	"TPV/r increased the dose-adjusted atorvastatin AUC0-∞ and Cmax by approximately ninefold (Table ​(Table2;2; Fig. ​Fig.33 and ​and4).4)."	"DDI clinical trial"	"interact with"	"atorvastatin"	"TPV/r"	"drug1"	""	""	"supports"	"23.00"	"Twenty-three subjects (11 men, 12 women) were recruited into this study."	"500/200"	"Oral"	"14-21"	"BID"	""	"10"	""	""	""	""	"Oral"	"1"	"SD"	""	"9.36"	"Fold"	"Increase"	"Single-dose PK parameters of atorvastatin, orthohydroxy atorvastatin, and parahydroxy atorvastatin after administration of atorvastatin 40 mg alone and coadministration of atorvastatin 10 mg and steady-state TPV/r 500 mg/200 mg twice daily (n = ..."	"8.61"	"Fold"	"Increase"	"Single-dose PK parameters of atorvastatin, orthohydroxy atorvastatin, and parahydroxy atorvastatin after administration of atorvastatin 40 mg alone and coadministration of atorvastatin 10 mg and steady-state TPV/r 500 mg/200 mg twice daily (n = ..."	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"09891c68-15eb-4269-9be0-06aab27acc3d"
"http://localhost/wiley/wiley16084850.html"	"annotat2@gmail.com"	"Gemfibrozil_interact with_atorvastatin"	"Gemfibrozil increased the AUC of atorvastatin (by 24%; 95% CI, −1% to 50%; P = .059), 2-hydroxyatorvastatin acid (by 51%; 95% CI, 28% to 70%; P < .001) and its lactone (by 29%; 95% CI, 13% to 53%; P = .003), and 4-hydroxyatorvastatin acid (by 82%; 95% CI, 60% to 126%; P < .001) and its lactone (by 28%; 95% CI, 15% to 51%; P = .001)"	"DDI clinical trial"	"interact with"	"Gemfibrozil"	"atorvastatin"	"drug1"	""	""	"supports"	"20.00"	"Two groups of 10 healthy volunteer subjects participated in 2 separate randomized crossover studies after giving written informed consent."	"20"	"Oral"	"1"	"SD"	""	"600"	""	""	""	""	"Oral"	"5"	"BID"	""	"124"	"Percent"	"Increase"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150%"	"117"	"Percent"	"Increase"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150%"	""	""	""	""	"84"	"Percent"	"Decrease"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150%"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"c17f1a29-f3a6-4a76-885d-c044f3e64ee5"
"http://localhost/wiley/wiley16084850.html"	"annotat2@gmail.com"	"Gemfibrozil_interact with_atorvastatin"	"Gemfibrozil increased the AUC of atorvastatin (by 24%; 95% CI, −1% to 50%; P = .059), 2-hydroxyatorvastatin acid (by 51%; 95% CI, 28% to 70%; P < .001) and its lactone (by 29%; 95% CI, 13% to 53%; P = .003), and 4-hydroxyatorvastatin acid (by 82%; 95% CI, 60% to 126%; P < .001) and its lactone (by 28%; 95% CI, 15% to 51%; P = .001)"	"DDI clinical trial"	"interact with"	"Gemfibrozil"	"atorvastatin"	"drug1"	""	""	"supports"	"20.00"	"Two groups of 10 healthy volunteer subjects participated in 2 separate randomized crossover studies after giving written informed consent."	"20"	"Oral"	"1"	"SD"	""	"600"	""	""	""	""	"Oral"	"5"	"BID"	""	"125"	"Percent"	"Increase"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150%"	"117"	"Percent"	"Increase"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150%"	""	""	""	""	"84"	"Percent"	"Decrease"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150%"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"c17f1a29-f3a6-4a76-885d-c044f3e64ee5"
"http://localhost/wiley/wiley16027403.html"	"annotat2@gmail.com"	"rosuvastatin_interact with_warfarin"	"The results indicated that rosuvastatin can enhance the anticoagulant effect of warfarin"	"DDI clinical trial"	"interact with"	"rosuvastatin"	"warfarin"	"drug1"	""	""	"refutes"	"25.00"	"In trial A (a randomized, double-blind, 2-period crossover study), 18 healthy volunteers were given rosuvastatin 40 mg or placebo on demand (o.d.) for 10 days with 1 dose of warfarin 25 mg on day 7. In trial B (an open-label, 2-period study), 7 patients receiving warfarin therapy with stable international normalized ratio values between 2 and 3 were coadministered rosuvastatin 10 mg o.d. for up to 14 days, which increased to rosuvastatin 80 mg if the international normalized ratio values were <3 at the end of this period"	"25"	"Oral"	"1"	"SD"	""	"40"	""	""	""	""	"Oral"	"10"	"Daily"	""	"1.1"	"UNK"	"Increase"	"Table I.  INR Summary Parameters in the Presence of Rosuvastatin and Placebo and Statistical Analysis of AU-INR0-t and maxINR (Trial A)ParameterSummary StatisticRosuvastatin + Warfarin (n = 18)Placebo + Warfarin (n = 18)Treatment Effectat Test P Value INR, international normalized ratio; AU-INR0-t, area under the INR-time curve from time 0 to the time of the last quantifiable measurement; maxINR, maximum INR; tmaxINR, time at which maxINR was observed; NA, not applicable. a   Ratio of rosuvastatin + warfarin/placebo + warfarin geometric least squares means for AU-INR0-t and maxINR. AU-INR0-tMean (SE)252 (9.62)228 (7.13)1.10< .0001maxINRMean (SE)2.43 (0.13)2.03 (20.3)1.19< .0001tmaxINR, hMedian (range)42 (24–60)36 (24–48)NANA"	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"e5ff1b22-caba-41eb-a3f7-03fda7c91435"
"http://localhost/wiley/wiley16027403.html"	"annotat2@gmail.com"	"warfarin_interact with_Rosuvastatin"	"Administration of the single dose of warfarin did not affect rosuvastatin systemic exposure. Rosuvastatin gmean AUC0-24 values of 182 and 195 ng•h/mL were obtained before and after warfarin dosing, respectively. The treatment effect (before/after ratio of geometric least squares means) for this parameter was 0.93, with a 90% CI of 0.86 to 1.02"	"DDI clinical trial"	"interact with"	"warfarin"	"Rosuvastatin"	"drug1"	""	""	"refutes"	"25.00"	"In trial A (a randomized, double-blind, 2-period crossover study), 18 healthy volunteers were given rosuvastatin 40 mg or placebo on demand (o.d.) for 10 days with 1 dose of warfarin 25 mg on day 7. In trial B (an open-label, 2-period study), 7 patients receiving warfarin therapy with stable international normalized ratio values between 2 and 3 were coadministered rosuvastatin 10 mg o.d. for up to 14 days, which increased to rosuvastatin 80 mg if the international normalized ratio values were <3 at the end of this period."	"40"	"Oral"	"10"	"Daily"	""	"25"	""	""	""	""	"Oral"	"1"	"SD"	""	"unchanged"	"None"	"None"	"Administration of the single dose of warfarin did not affect rosuvastatin systemic exposure. Rosuvastatin gmean AUC0-24 values of 182 and 195 ng•h/mL were obtained before and after warfarin dosing, respectively. The treatment effect (before/after ratio of geometric least squares means) for this parameter was 0.93, with a 90% CI of 0.86 to 1.02"	""	""	""	""	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"3f342959-7468-46e1-8a73-f417d082aa6d"
"http://localhost/PMC/PMC90851.html"	"annotat2@gmail.com"	"Nelfinavir_interact with_simvastatin"	"Nelfinavir increased the steady-state area under the plasma concentration-time curve during one dosing period (AUCτ) of atorvastatin 74% and the maximum concentration (Cmax) of atorvastatin 122% and increased the AUCτ of simvastatin 505% and the Cmax of simvastatin 517%. Neither atorvastatin nor simvastatin appeared to alter the pharmacokinetics of nelfinavir."	"DDI clinical trial"	"interact with"	"Nelfinavir"	"simvastatin"	"drug1"	""	""	"supports"	"32.00"	"The 32 enrolled subjects consisted of 12 Caucasians (six males and six females), 15 African Americans (eight males and seven females), and five Hispanics (two males and three females)."	"1250"	"Oral"	"14"	"BID"	""	"20"	""	""	""	""	"Oral"	"28"	"QD"	""	"6.05"	"Fold"	"Increase"	"Pharmacokinetic parameters of atorvastatin and simvastatin"	"6.17"	"Fold"	"Increase"	"Pharmacokinetic parameters of atorvastatin and simvastatin"	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"a39b7660-ca77-4881-97bf-cfa4843ed3c4"
"http://localhost/PMC/PMC3769672.html"	"annotat2@gmail.com"	"ritonavir_interact with_rivaroxaban"	"Steady-state ritonavir significantly increased the AUC and Cmax of rivaroxaban. The mean AUC increased by 153% (90% CI 134%, 174%) and the mean Cmax increased by 55% (90% CI 41%, 69%) compared with rivaroxaban alone"	"DDI clinical trial"	"interact with"	"ritonavir"	"rivaroxaban"	"drug1"	""	""	"supports"	"18.00"	"Eighteen subjects were enrolled in the study."	"10"	"Oral"	"1"	"SD"	""	"600"	""	""	""	""	"Oral"	"5"	"BID"	""	"2.53"	"Fold"	"Increase"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"1.55"	"UNK"	"Increase"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"0.39"	"Fold"	"Decrease"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"unchanged"	"None"	"None"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"f3e4d137-a2ef-41a0-94e5-ae37c3ce0749"
"http://localhost/PMC/PMC3769672.html"	"annotat2@gmail.com"	"rivaroxaban_interact with_midazolam"	"Co-administration with rivaroxaban slightly decreased the mean AUC of midazolam by 11% compared with midazolam alone, but this was not statistically significant (90% CI −25%, 5%). The mean Cmax was virtually unaffected. Conversely, the mean AUC of α-hydroxy-midazolam remained almost the same with co-administration of rivaroxaban and midazolam compared with midazolam alone, but the mean Cmax was increased by 11%. This change was not statistically significant (90% CI −23%, 59%)."	"DDI clinical trial"	"interact with"	"rivaroxaban"	"midazolam"	"drug1"	""	""	"refutes"	"12.00"	"A total of 12 subjects were enrolled."	"20"	"Oral"	"1"	"SD"	""	"7.5"	""	""	""	""	"Oral"	"1"	"SD"	""	"unchanged"	"None"	"None"	"Co-administration with rivaroxaban slightly decreased the mean AUC of midazolam by 11% compared with midazolam alone, but this was not statistically significant (90% CI −25%, 5%). The mean Cmax was virtually unaffected. Conversely, the mean AUC of α-hydroxy-midazolam remained almost the same with co-administration of rivaroxaban and midazolam compared with midazolam alone, but the mean Cmax was increased by 11%. This change was not statistically significant (90% CI −23%, 59%)."	"unchanged"	"None"	"None"	"Co-administration with rivaroxaban slightly decreased the mean AUC of midazolam by 11% compared with midazolam alone, but this was not statistically significant (90% CI −25%, 5%). The mean Cmax was virtually unaffected. Conversely, the mean AUC of α-hydroxy-midazolam remained almost the same with co-administration of rivaroxaban and midazolam compared with midazolam alone, but the mean Cmax was increased by 11%. This change was not statistically significant (90% CI −23%, 59%)."	""	""	""	""	"unchanged"	"None"	"None"	"The tmax and t1/2 of midazolam and its metabolite remained similar in the presence or absence of rivaroxaban."	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"876832b0-fd4c-4dc6-b342-f78ff86304b8"
"http://localhost/wiley/wiley18784280.html"	"annotat2@gmail.com"	"digoxin_interact with_aliskiren"	"Coadministration of aliskiren with digoxin had no significant effect on aliskiren AUCτ (ratio of geometric means, 1.02 [90% CI: 0.93, 1.13]; P = .706) or Cmax,ss (0.98 [90% CI: 0.80, 1.19]; P = .830; Figure 3) or on median tmax,ss. Aliskiren CL/F was also unchanged by coadministration with digoxin (Table II)."	"DDI clinical trial"	"interact with"	"digoxin"	"aliskiren"	"drug1"	""	""	"refutes"	"22.00"	"Three open-label, multiple-dose studies in healthy subjects investigated the pharmacokinetic interactions between aliskiren 300 mg and digoxin 0.25 mg (n = 22), atorvastatin 80 mg (n = 21), or ketoconazole 200 mg bid (n = 21). Coadministration with aliskiren resulted in changes of <30% in AUCτ and Cmax,ss of digoxin, atorvastatin, o-hydroxy-atorvastatin, and ρ-hydroxy-atorvastatin, indicating no clinically significant interaction with P-glycoprotein or CYP3A4 substrates"	"300"	"Oral"	"7"	"Daily"	""	"0.25"	""	""	""	""	"Oral"	"9"	"Daily"	""	"unchanged"	"None"	"None"	"Table II.  Pharmacokinetic Parameters for Aliskiren Administered Alone and in Combination With Digoxin, Atorvastatin, or KetoconazoleParameterAliskiren/Digoxin StudyAliskiren/Atorvastatin StudyAliskiren/Ketoconazole StudyAliskiren 300 mg (n = 21)Aliskiren 300 mg + Digoxin 0.25 mg (n = 19)Aliskiren 300 mg (n = 20)Aliskiren 300 mg + Atorvastatin 80 mg (n = 20)Aliskiren 300 mg (n = 21)Aliskiren 300 mg + Ketoconazole 200 mg (n = 20) Values are presented as geometric mean except for CL/F values, which are presented as arithmetic mean ± SD, and tmax values, which are presented as the median (range). ND, not determined. Cmax,ss, ng/mL246240392588369675tmax,ss, h1.0 (0.6–6.0)2.0 (0.6–6.0)2.03 (0.50–6.00)2.00 (0.50–6.02)2.0 (0.5–4.1)1.0 (0.5–4.0)AUCτ, ng·h/mL160515932180320121063750Cmin,ss, ng/mL23.724.4NDND30.048.0CL/F, L/h194.7 ± 57.0196.4 ± 58.7149.3 ± 63.398.4 ± 32.9162.4 ± 85.4"	"unchanged"	"None"	"None"	"Table II.  Pharmacokinetic Parameters for Aliskiren Administered Alone and in Combination With Digoxin, Atorvastatin, or KetoconazoleParameterAliskiren/Digoxin StudyAliskiren/Atorvastatin StudyAliskiren/Ketoconazole StudyAliskiren 300 mg (n = 21)Aliskiren 300 mg + Digoxin 0.25 mg (n = 19)Aliskiren 300 mg (n = 20)Aliskiren 300 mg + Atorvastatin 80 mg (n = 20)Aliskiren 300 mg (n = 21)Aliskiren 300 mg + Ketoconazole 200 mg (n = 20) Values are presented as geometric mean except for CL/F values, which are presented as arithmetic mean ± SD, and tmax values, which are presented as the median (range). ND, not determined. Cmax,ss, ng/mL246240392588369675tmax,ss, h1.0 (0.6–6.0)2.0 (0.6–6.0)2.03 (0.50–6.00)2.00 (0.50–6.02)2.0 (0.5–4.1)1.0 (0.5–4.0)AUCτ, ng·h/mL160515932180320121063750Cmin,ss, ng/mL23.724.4NDND30.048.0CL/F, L/h194.7 ± 57.0196.4 ± 58.7149.3 ± 63.398.4 ± 32.9162.4 ± 85.4"	"unchanged"	"None"	"None"	"Table II.  Pharmacokinetic Parameters for Aliskiren Administered Alone and in Combination With Digoxin, Atorvastatin, or KetoconazoleParameterAliskiren/Digoxin StudyAliskiren/Atorvastatin StudyAliskiren/Ketoconazole StudyAliskiren 300 mg (n = 21)Aliskiren 300 mg + Digoxin 0.25 mg (n = 19)Aliskiren 300 mg (n = 20)Aliskiren 300 mg + Atorvastatin 80 mg (n = 20)Aliskiren 300 mg (n = 21)Aliskiren 300 mg + Ketoconazole 200 mg (n = 20) Values are presented as geometric mean except for CL/F values, which are presented as arithmetic mean ± SD, and tmax values, which are presented as the median (range). ND, not determined. Cmax,ss, ng/mL246240392588369675tmax,ss, h1.0 (0.6–6.0)2.0 (0.6–6.0)2.03 (0.50–6.00)2.00 (0.50–6.02)2.0 (0.5–4.1)1.0 (0.5–4.0)AUCτ, ng·h/mL160515932180320121063750Cmin,ss, ng/mL23.724.4NDND30.048.0CL/F, L/h194.7 ± 57.0196.4 ± 58.7149.3 ± 63.398.4 ± 32.9162.4 ± 85.4"	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"995c4075-f5f9-4c3c-af97-68d42a60420b"
"http://localhost/wiley/wiley18784280.html"	"annotat2@gmail.com"	"atorvastatin_interact with_aliskiren"	"Coadministration of aliskiren with atorvastatin significantly increased aliskiren AUCτ by 47% (ratio of geometric means, 1.47 [90% CI: 1.29, 1.67]; P < .001) and Cmax,ss by 50% (geometric mean ratio 1.50 [90% CI: 1.22, 1.85]; P = .003; Figure 3)"	"DDI clinical trial"	"interact with"	"atorvastatin"	"aliskiren"	"drug1"	""	""	"supports"	"21.00"	"Three open-label, multiple-dose studies in healthy subjects investigated the pharmacokinetic interactions between aliskiren 300 mg and digoxin 0.25 mg (n = 22), atorvastatin 80 mg (n = 21), or ketoconazole 200 mg bid (n = 21)."	"300"	"Oral"	"7"	"Daily"	""	"80"	""	""	""	""	"Oral"	"4"	"Daily"	""	"1.46"	"Fold"	"Increase"	"Table II.  Pharmacokinetic Parameters for Aliskiren Administered Alone and in Combination With Digoxin, Atorvastatin, or Ketoconazole"	"1.5"	"Fold"	"Increase"	"Table II.  Pharmacokinetic Parameters for Aliskiren Administered Alone and in Combination With Digoxin, Atorvastatin, or Ketoconazole"	"34"	"Percent"	"Decrease"	"Table II.  Pharmacokinetic Parameters for Aliskiren Administered Alone and in Combination With Digoxin, Atorvastatin, or Ketoconazole"	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"9b8b6b13-807d-4493-adad-26006b005131"
"http://localhost/wiley/wiley17301736.html"	"annotat2@gmail.com"	"arone_interact with_simvastatin"	"Amiodarone increased simvastatin acid AUC (area under the plasma concentration–time curve)0–24 h, peak plasma concentration (Cmax), and t1/2 by 73% (P=0.02), 100% (P=0.02), and 48% (P=0.06), respectively, whereas it did not significantly alter pravastatin pharmacokinetics"	"DDI clinical trial"	"interact with"	"arone"	"simvastatin"	"drug1"	""	""	"supports"	"12.00"	"Twelve white occidental healthy volunteers (seven male and five female subjects) aged 19–43 years were enrolled in this study."	"40"	"Oral"	"2"	"SD"	""	"400"	""	""	""	""	"Oral"	"3"	"SD"	""	"154"	"Percent"	"Increase"	"Amiodarone significantly increased the mean AUC0–24 h of both the parent simvastatin lactone (by 73% P=0.02) and of simvastatin acid (by 78% P=0.02) (Table 1 and Figure 2). The Cmax of simvastatin acid was increased by 100% by amiodarone (P=0.02). Amiodarone had no significant effect on the t1/2 of simvastatin and a borderline effect on the t1/2 of simvastatin acid (P=0.06).Table 1. Pharmacokinetics of simvastatin and pravastatin in the absence and presence of amiodarone CmaxT1/2AUC0–24 h (ng ml−1)(h)(ng h ml−1)AUC, area under the plasma concentration–time curve; CI, confidence interval; Cmax, peak plasma concentration; T1/2, half-life.Results are expressed as mean±SD; *P=0.02 vs in the absence of amiodarone. The point estimates and their confidence intervals refer to 90% confidence intervals about the geometric mean ratio (point estimates) of the observed pharmacokinetic measures with amiodarone and without amiodarone.Simvastatin acid2.4±1.35.0±1.523.1±12.9Simvastatin acid+amiodarone4.3±3.1*7.4±3.740.7±28.5*Point estimate (90% CI)156% (109–223%) 154% (109–216%)"	"156"	"Percent"	"Increase"	"Amiodarone significantly increased the mean AUC0–24 h of both the parent simvastatin lactone (by 73% P=0.02) and of simvastatin acid (by 78% P=0.02) (Table 1 and Figure 2). The Cmax of simvastatin acid was increased by 100% by amiodarone (P=0.02). Amiodarone had no significant effect on the t1/2 of simvastatin and a borderline effect on the t1/2 of simvastatin acid (P=0.06).Table 1. Pharmacokinetics of simvastatin and pravastatin in the absence and presence of amiodarone CmaxT1/2AUC0–24 h (ng ml−1)(h)(ng h ml−1)AUC, area under the plasma concentration–time curve; CI, confidence interval; Cmax, peak plasma concentration; T1/2, half-life.Results are expressed as mean±SD; *P=0.02 vs in the absence of amiodarone. The point estimates and their confidence intervals refer to 90% confidence intervals about the geometric mean ratio (point estimates) of the observed pharmacokinetic measures with amiodarone and without amiodarone.Simvastatin acid2.4±1.35.0±1.523.1±12.9Simvastatin acid+amiodarone4.3±3.1*7.4±3.740.7±28.5*Point estimate (90% CI)156% (109–223%) 154% (109–216%)"	""	""	""	""	"unchanged"	"None"	"None"	"Amiodarone significantly increased the mean AUC0–24 h of both the parent simvastatin lactone (by 73% P=0.02) and of simvastatin acid (by 78% P=0.02) (Table 1 and Figure 2). The Cmax of simvastatin acid was increased by 100% by amiodarone (P=0.02). Amiodarone had no significant effect on the t1/2 of simvastatin and a borderline effect on the t1/2 of simvastatin acid (P=0.06).Table 1. Pharmacokinetics of simvastatin and pravastatin in the absence and presence of amiodarone CmaxT1/2AUC0–24 h (ng ml−1)(h)(ng h ml−1)AUC, area under the plasma concentration–time curve; CI, confidence interval; Cmax, peak plasma concentration; T1/2, half-life.Results are expressed as mean±SD; *P=0.02 vs in the absence of amiodarone. The point estimates and their confidence intervals refer to 90% confidence intervals about the geometric mean ratio (point estimates) of the observed pharmacokinetic measures with amiodarone and without amiodarone.Simvastatin acid2.4±1.35.0±1.523.1±12.9Simvastatin acid+amiodarone4.3±3.1*7.4±3.740.7±28.5*Point estimate (90% CI)156% (109–223%) 154% (109–216%)"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"ec9255d4-978d-4103-83f5-6762222c82c0"
"http://localhost/PMC/PMC1884190.html"	"annotat2@gmail.com"	"ketoconazole_interact with_rosuvastatin"	"The geometric mean (gmean) plasma concentrations of rosuvastatin over time were similar when rosuvastatin was coadministered with ketoconazole and placebo (Figure 1)."	"DDI clinical trial"	"interact with"	"ketoconazole"	"rosuvastatin"	"drug1"	""	""	"refutes"	"14.00"	"Fourteen male Caucasian volunteers were enrolled"	"200"	"Oral"	"7"	"BID"	""	"80"	""	""	""	""	"Oral"	"1"	"SD"	""	"unchanged"	"None"	"None"	"Summary pharmacokinetic parameters of rosuvastatin, and results of the statistical analysis of the plasma AUC(0,t) and Cmax of rosuvastatin, when coadministered with ketoconazole and placebo"	"unchanged"	"None"	"None"	"Summary pharmacokinetic parameters of rosuvastatin, and results of the statistical analysis of the plasma AUC(0,t) and Cmax of rosuvastatin, when coadministered with ketoconazole and placebo"	""	""	""	""	""	""	""	""	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"623ef0a5-fda6-4eb7-bb2f-d8da6102bc0e"
"http://localhost/PMC/PMC3769672.html"	"annotat2@gmail.com"	"ketoconazole_interact with_rivaroxaban"	"Co-administration with steady-state ketoconazole significantly increased the plasma concentrations of a single dose of rivaroxaban 10 mg compared with rivaroxaban alone. The mean AUC increased by 82% (90% CI 59%, 108%) and the mean Cmax increased by 53% (90% CI 27%, 85%)."	"DDI clinical trial"	"interact with"	"ketoconazole"	"rivaroxaban"	"drug1"	""	""	"supports"	"12.00"	"In the ketoconazole 200 mg study, 12 subjects were enrolled"	"10"	"Oral"	"1"	"SD"	""	"200"	""	""	""	""	"Oral"	"4"	"Daily"	""	"1.82"	"UNK"	"Increase"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"1.53"	"UNK"	"Increase"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"0.55"	"UNK"	"Decrease"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"unchanged"	"None"	"None"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"74830401-1acc-4f84-bb7e-b9826e762c7d"
"http://localhost/PMC/PMC3769672.html"	"annotat2@gmail.com"	"ketoconazole_interact with_rivaroxaban"	"Co-administration with steady-state ketoconazole significantly increased the plasma concentrations of a single dose of rivaroxaban 10 mg compared with rivaroxaban alone. The mean AUC increased by 82% (90% CI 59%, 108%) and the mean Cmax increased by 53% (90% CI 27%, 85%)."	"DDI clinical trial"	"interact with"	"ketoconazole"	"rivaroxaban"	"drug1"	""	""	"supports"	"20.00"	"In the ketoconazole 400 mg study, a total of 20 subjects were enrolled"	"10"	"Oral"	"10"	"Daily"	""	"400"	""	""	""	""	"Oral"	"5"	"Daily"	""	"2.58"	"Fold"	"Increase"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"1.72"	"UNK"	"Increase"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"0.39"	"Fold"	"Decrease"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"unchanged"	"None"	"None"	"Pharmacokinetic parameters of rivaroxaban (10 mg) administered alone or in combination with ketoconazole 200 mg once daily or 400 mg once daily, ritonavir 600 mg twice daily, clarithromycin 500 mg twice daily, erythromycin 500 mg three times daily or ..."	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"74830401-1acc-4f84-bb7e-b9826e762c7d"
"http://localhost/PMC/PMC2764168.html"	"annotat2@gmail.com"	"TPV/r_interact with_rosuvastatin"	"With TPV/r coadministration, the GM AUC for rosuvastatin was 38.6 ng·h/ml, a 37% increase compared with that of rosuvastatin alone (P = 0.0006) (Fig. ​(Fig.11 and ​and2).2)."	"DDI clinical trial"	"interact with"	"TPV/r"	"rosuvastatin"	"drug1"	""	""	"supports"	"29.00"	"Of the 29 subjects (5 women, 24 men), 16 evaluable subjects completed the study."	"500/200"	"Oral"	"11"	"BID"	""	"10"	""	""	""	""	"Oral"	"1"	"SD"	""	"1.37"	"Fold"	"Increase"	"PK parameters of rosuvastatin alone or rosuvastatin plus TPV/ra"	"2.23"	"Fold"	"Increase"	"PK parameters of rosuvastatin alone or rosuvastatin plus TPV/ra"	"0.73"	"Fold"	"Decrease"	"PK parameters of rosuvastatin alone or rosuvastatin plus TPV/ra"	"2.29"	"Fold"	"Increase"	"PK parameters of rosuvastatin alone or rosuvastatin plus TPV/ra"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"a567625a-bd7c-4c56-bc5c-6080aae6c3e7"
"http://localhost/PMC/PMC3769672.html"	"annotat2@gmail.com"	"midazolam_interact with_rivaroxaban"	"Co-administration with midazolam led to an increase in rivaroxaban median tmax from 1.5 h to 4.0 h and slightly decreased the rivaroxaban mean Cmax by 12% compared with rivaroxaban alone, a change that was not statistically significant (90% CI −28%, 7%). Rivaroxaban mean AUC remained almost unchanged."	"DDI clinical trial"	"interact with"	"midazolam"	"rivaroxaban"	"drug1"	""	""	"refutes"	"12.00"	"A total of 12 subjects were enrolled."	"20"	"Oral"	"1"	"SD"	""	"7.5"	""	""	""	""	"Oral"	"1"	"SD"	""	"unchanged"	"None"	"None"	"Pharmacokinetic parameters of rivaroxaban administered alone or in combination with midazolam 7.5 mg (mean/CV [range]) and comparison of pharmacokinetic characteristics between treatments based on anova results"	"unchanged"	"None"	"None"	"Pharmacokinetic parameters of rivaroxaban administered alone or in combination with midazolam 7.5 mg (mean/CV [range]) and comparison of pharmacokinetic characteristics between treatments based on anova results"	""	""	""	""	"unchanged"	"None"	"None"	"The tmax and t1/2 of midazolam and its metabolite remained similar in the presence or absence of rivaroxaban."	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"a6805b92-854b-4a86-a3c9-200c14c70bce"
"http://localhost/wiley/wiley16084850.html"	"annotat2@gmail.com"	"Gemfibrozil_interact with_atorvastatin"	"Gemfibrozil increased the AUC of atorvastatin (by 24%; 95% CI, −1% to 50%; P = .059), 2-hydroxyatorvastatin acid (by 51%; 95% CI, 28% to 70%; P < .001) and its lactone (by 29%; 95% CI, 13% to 53%; P = .003), and 4-hydroxyatorvastatin acid (by 82%; 95% CI, 60% to 126%; P < .001) and its lactone (by 28%; 95% CI, 15% to 51%; P = .001)."	"DDI clinical trial"	"interact with"	"Gemfibrozil"	"atorvastatin"	"drug1"	""	""	"supports"	"20.00"	"Two groups of 10 healthy volunteer subjects participated in 2 separate randomized crossover studies after giving written informed consent."	"20"	"Oral"	"1"	"SD"	""	"600"	""	""	""	""	"Oral"	"5"	"BID"	""	"124"	"Percent"	"Increase"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150"	"117"	"Percent"	"Increase"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150"	""	""	""	""	"84"	"Percent"	"Decrease"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"5120b831-2ba8-40fc-ac63-4b513f6860fa"
"http://localhost/wiley/wiley16084850.html"	"annotat2@gmail.com"	"Gemfibrozil_interact with_atorvastatin"	"Gemfibrozil increased the AUC of atorvastatin (by 24%; 95% CI, −1% to 50%; P = .059), 2-hydroxyatorvastatin acid (by 51%; 95% CI, 28% to 70%; P < .001) and its lactone (by 29%; 95% CI, 13% to 53%; P = .003), and 4-hydroxyatorvastatin acid (by 82%; 95% CI, 60% to 126%; P < .001) and its lactone (by 28%; 95% CI, 15% to 51%; P = .001)."	"DDI clinical trial"	"interact with"	"Gemfibrozil"	"atorvastatin"	"drug1"	""	""	"supports"	"20.00"	"Two groups of 10 healthy volunteer subjects participated in 2 separate randomized crossover studies after giving written informed consent."	"20"	"Oral"	"1"	"SD"	""	"600"	""	""	""	""	"Oral"	"5"	"BID"	""	"125"	"Percent"	"Increase"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150%"	"117"	"Percent"	"Increase"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150%"	""	""	""	""	"84"	"Percent"	"Decrease"	"Table II. Pharmacokinetic variables of atorvastatin and its metabolites in 10 healthy subjects after single 20-mg dose of atorvastatin on day 3 of 5-day treatment with 600 mg gemfibrozil or placebo twice daily   Gemfibrozil phase (% of control)VariablePlacebo phaseGemfibrozil phaseMean and range95% CIValues are shown as mean ± SD unless otherwise indicated; tmax data are given as median and range.AUC(0–72), Area under plasma concentration-time curve from time 0 to 72 hours.*P < .05.†P < .005.‡P < .0005.Atorvastatin (acid)       Cmax (ng/mL)8.2 ± 3.59.6 ± 4.0117% (31%–227%)>77%–184%   tmax (h)0.5 (0.5–2.5)0.75 (0.5–2)—    t½ (h)10.7 ± 2.29.0 ± 1.77†84% (69%–109%)77%–92%   AUC(0–72) (ng×h/mL)34.7 ± 11.543.3 ± 15.7125% (76%–161%)100%–152%   AUC(0-∞) (ng×h/mL)35.2 ± 11.843.6 ± 15.8124% (76%–160%)99%–150%"	"undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined|undefined"	""	""	""	""	""	""	"5120b831-2ba8-40fc-ac63-4b513f6860fa"